10x Genomics (TXG) 10-K 27 Feb 20 2019 FY Annual report Financial data

Cover Page

Cover Page - USD ($)	12 Months Ended
	Dec. 31, 2019	Jan. 31, 2020	Jun. 28, 2019
Entity Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Document Annual Report	true
Document Transition Report	false
Entity Registrant Name	10x Genomics, Inc.
Entity Central Index Key	0001770787
Title of 12(b) Security	Class A common stock
Trading Symbol	TXG
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Well-known Seasoned Issuer	No
Entity File Number	001-39035
Entity Voluntary Filers	No
Entity Tax Identification Number	45-5614458
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	6230 Stoneridge Mall Road
Entity Address, Address Line Two	Pleasanton
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94588
City Area Code	925
Local Phone Number	401-7300
Entity Public Float			$ 0
Common Class A [Member]
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		21,282,464
Common Class B [Member]
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		75,269,430

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 424,166	$ 65,080
Accounts receivable, net	33,371	28,088
Inventory	15,270	8,570
Prepaid expenses and other current assets	8,033	4,498
Total current assets	480,840	106,236
Property and equipment, net	48,821	11,127
Restricted cash	52,327	5,008
Other assets	23,935	1,939
Total assets	605,923	124,310
Current liabilities:
Accounts payable	13,028	8,792
Accrued compensation and related benefits	12,394	7,047
Accrued expenses and other current liabilities	24,448	9,941
Term loans, current portion	9,882	4,187
Deferred revenue, current	3,297	2,395
Total current liabilities	63,049	32,362
Term loans, noncurrent portion	19,837	25,489
Accrued contingent liabilities	68,658	38,000
Accrued license fee, noncurrent	16,251
Deferred revenue, noncurrent	834	1,102
Deferred rent, noncurrent	16,120	3,329
Other noncurrent liabilities	1,091	771
Total liabilities	185,840	101,053
Commitments and contingencies (Note 6)
Convertible preferred stock, $0.00001 par value, no shares authorized and no shares issued and outstanding as of December 31, 2019; 67,904,871 shares authorized and 67,704,278 shares issued and outstanding as of December 31, 2018; aggregate liquidation preference of $242,588 as of December 31, 2018		243,244
Stockholders' equity (deficit):
Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued and outstanding as of December 31, 2019; no shares authorized, issued or outstanding as of December 31, 2018
Common stock, $0.00001 par value; 1,100,000,000 shares authorized and 96,241,596 shares issued and outstanding as of December 31, 2019; 190,955,000 shares authorized and 14,549,801 shares issued and outstanding as of December 31, 2018	2	1
Additional paid-in capital	682,494	11,165
Accumulated deficit	(262,367)	(231,116)
Accumulated other comprehensive loss	(46)	(37)
Total stockholders' equity (deficit)	420,083	(219,987)
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	$ 605,923	$ 124,310

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Convertible Preferred Stock, Par Value	$ 0.00001	$ 0.00001
Convertible Preferred Stock, Shares Authorized	0	67,904,871
Convertible Preferred Stock, Shares Issued	0	67,704,278
Convertible Preferred Stock, Shares Outstanding	0	67,704,278
Convertible Preferred Stock, Liquidation Preference		$ 242,588
Preferred Stock, Par Value	$ 0.00001	$ 0.00001
Preferred Stock, Shares Authorized	100,000,000	0
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value	$ 0.00001	$ 0.00001
Common Stock, Shares Authorized	1,100,000,000	190,955,000
Common Stock, Shares Issued	96,241,596	14,549,801
Common Stock, Outstanding	96,241,596	14,549,801

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenue	$ 245,893	$ 146,313	$ 71,085
Cost of revenue	61,033	28,661	10,560
Gross profit	184,860	117,652	60,525
Operating expenses:
Research and development	83,097	47,537	32,164
In-process research and development		62,363
Selling, general and administrative	130,834	87,936	46,736
Accrued contingent liabilities	1,502	30,580
Total operating expenses	215,433	228,416	78,900
Loss from operations	(30,573)	(110,764)	(18,375)
Other income (expense):
Interest income	2,805	1,024	308
Interest expense	(3,079)	(2,409)	(811)
Other income (expense), net	(186)	(249)	137
Total other expense	(460)	(1,634)	(366)
Loss before provision for income taxes	(31,033)	(112,398)	(18,741)
Provision for income taxes	218	87	21
Net loss	(31,251)	(112,485)	(18,762)
Other comprehensive loss
Foreign currency translation adjustment	(9)	(22)	(15)
Comprehensive loss	$ (31,260)	$ (112,507)	$ (18,777)
Net loss per share, basic and diluted	$ (0.80)	$ (8.40)	$ (1.62)
Weighted-average shares used to compute net loss per share, basic and diluted	39,091,366	13,392,273	11,587,751

Consolidated Statements of Conv

Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common stock [Member]	Additional paid-in capital [Member]	Accumulated deficit	Accumulated other comprehensive income (loss)	Common class A [Member]	Common class A [Member]Common stock [Member]	Common class A [Member]Additional paid-in capital [Member]	Common class B [Member]	Common class B [Member]Common stock [Member]	Common class B [Member]Additional paid-in capital [Member]	Convertible preferred stock [Member]	Series D convertible preferred stock [Member]	Non vested common class A [Member]Common stock [Member]	Series D1 convertible preferred stock [Member]
Beginning balance at Dec. 31, 2016	$ (96,431)	$ 1	$ 3,437	$ (99,869)
Beginning balance, shares at Dec. 31, 2016		11,330,679
Beginning balance of temporary equity at Dec. 31, 2016												$ 138,450
Beginning balance of temporary equity, shares at Dec. 31, 2016												55,264,133
Stock issued during the period new issue												$ 19,964
Stock issued during the period new issue, shares												4,466,080
Issuance of Class A common stock upon exercise of options						$ 926		$ 926
Issuance of Class A common stock upon exercise of options, shares							1,628,251
Repurchase of unvested Class A common stock related to early exercised options, shares														(75,000)
Issuance of Class A common stock upon initial public offering, net of issuance costs, shares												4,466,080
Vesting of shares subject to repurchase, including early exercised options	112		112
Stock-based compensation	1,661		1,661
Net loss	(18,762)			(18,762)
Other comprehensive loss	(15)				$ (15)
Ending balance at Dec. 31, 2017	(112,509)	$ 1	6,136	(118,631)	(15)
Ending balance, shares at Dec. 31, 2017		12,883,930
Ending balance of temporary equity at Dec. 31, 2017												$ 158,414
Ending balance of temporary equity, shares at Dec. 31, 2017												59,730,213
Issuance of Class A common stock upon exercise of options						1,173		1,173
Issuance of Class A common stock upon exercise of options, shares							1,508,762
Issuance of warrants to purchase common stock	150		150
Issuance of convertible preferred stock, net of issuance costs, shares													5,224,658		2,749,407
Issuance of convertible preferred stock, net of issuance costs													$ 49,878		$ 34,952
Issuance of Class A common stock for in-process research and development, shares							157,109
Issuance of Class A common stock for in-process research and development						792		792
Vesting of shares subject to repurchase, including early exercised options	256		256
Stock-based compensation	2,658		2,658
Net loss	(112,485)			(112,485)
Other comprehensive loss	(22)				(22)
Ending balance at Dec. 31, 2018	(219,987)	$ 1	11,165	(231,116)	(37)
Ending balance, shares at Dec. 31, 2018		14,549,801
Ending balance of temporary equity at Dec. 31, 2018	$ 243,244											$ 243,244
Ending balance of temporary equity, shares at Dec. 31, 2018	67,704,278											67,704,278
Stock issued during the period new issue, shares							11,500,000
Issuance of Class A common stock upon exercise of options						$ 3,435		$ 3,435
Issuance of Class A common stock upon exercise of options, shares							2,226,493
Conversion of convertible preferred stock into Class B common stock, shares										67,704,278
Conversion of convertible preferred stock into Class B common stock									$ 243,244	$ 1	$ 243,243
Conversion of convertible preferred stock into Class B common stock, shares												(67,704,278)
Conversion of convertible preferred stock into Class B common stock												$ (243,244)
Issuance of Class A common stock upon initial public offering, net of issuance costs, shares							11,500,000
Cashless exercise of Class A common stock warrants, shares							261,024
Vesting of shares subject to repurchase, including early exercised options	$ 494		494
Stock-based compensation	13,333		13,333
Net loss	(31,251)			(31,251)
Other comprehensive loss	(9)				(9)
Ending balance at Dec. 31, 2019	$ 420,083	$ 2	$ 682,494	$ (262,367)	$ (46)
Ending balance, shares at Dec. 31, 2019		96,241,596
Ending balance of temporary equity, shares at Dec. 31, 2019	0

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operating activities:
Net loss	$ (31,251)	$ (112,485)	$ (18,762)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	7,066	3,905	4,305
Stock-based compensation	13,333	2,658	1,661
Class A common stock issued for in-process research and development		792
Loss on disposal of property and equipment	614	251
Accretion of discount on term loan	101	455	149
Changes in operating assets and liabilities:
Accounts receivable	(5,284)	(14,747)	(5,131)
Inventory	(6,699)	(3,732)	(1,995)
Prepaid expenses and other current assets	(3,535)	(2,429)	(702)
Other assets	(251)	(999)	33
Accounts payable	4,901	2,587	3,034
Accrued compensation and other related benefits	5,292	2,600	3,498
Deferred revenue	634	1,673	1,317
Accrued contingent liabilities	30,658	38,000
Accrued expenses and other current liabilities	5,771	1,701	1,844
Deferred rent, noncurrent	12,730	3,328	(68)
Other noncurrent liabilities	547	33	118
Net cash provided by (used in) operating activities	34,627	(76,409)	(10,699)
Investing activities:
Purchases of property and equipment	(42,742)	(6,284)	(3,756)
Purchases of intangible assets	(25)	(425)
Net cash used in investing activities	(42,767)	(6,709)	(3,756)
Financing activities:
Proceeds from term loans		19,512
Payments on term loans		(704)
Proceeds from borrowings under revolver	11,000
Payments on borrowings under revolver	(11,000)
Payments on capital lease obligations		(69)	(393)
Proceeds from issuance of preferred stock, net of issuance costs		84,830	19,964
Repurchase of unvested common stock related to early exercised shares			(80)
Proceeds from issuance of common stock upon initial public offering, net of issuance costs	410,824
Proceeds from issuance of common stock upon exercise of stock options	3,766	1,798	1,092
Net cash provided by financing activities	414,590	105,367	20,583
Effect of exchange rates on changes in cash, cash equivalents, and restricted cash	(45)	(18)	(14)
Net increase in cash, cash equivalents, and restricted cash	406,405	22,231	6,114
Cash, cash equivalents, and restricted cash at beginning of year	70,088	47,857	41,743
Cash, cash equivalents, and restricted cash at end of year	476,493	70,088	47,857
Supplemental disclosures of cash flow information:
Cash paid for interest	2,250	1,824	658
Cash paid for taxes	22	6
Noncash investing and financing activities
Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities	4,492	$ 2,260	$ 250
Conversion of convertible preferred stock into common stock upon initial public offering	243,244
Purchase of technology licenses under financing arrangement	$ 22,099

Description of Business and Bas

Description of Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	1. Description of Business and Basis of Presentation Organization and Description of Business 10x Genomics, Inc. (the “Company”) was incorporated in the state of Delaware on July 2, 2012. The Company’s integrated solutions include the Company’s Chromium instruments, which are referred to as “instruments,” its enzymes, reagents, microfluidic chips and other consumable products, which are referred to as “consumables,” and software for analyzing biological systems. These solutions guide customers through the workflow from sample preparation to next-generation sequencing to subsequent analysis and visualization. Each of the Company’s solutions is designed to interrogate a major class of biological information that is impactful to researchers. The Company began commercial and manufacturing operations and selling its instruments and consumables in 2015. The Company is headquartered in Pleasanton, California and has wholly-owned subsidiaries in Sweden, Netherlands, Singapore, Germany and China. Initial Public Offering The Company’s registration statement on Form S-1 Immediately prior to the completion of the IPO, 67,704,278 shares of convertible preferred stock then outstanding converted into an equivalent number of shares of Class B common stock, 8,050,000 shares of Historical Class A common stock converted into an equivalent number of shares of Class B common stock, and 8,095,382 shares of Historical Class B common stock converted into an equivalent number of shares of Class A common stock. The Company has reflected the renaming of Historical Class A common stock and Historical Class B common stock to Class B common stock and Class A common stock, respectively, throughout the document and all instances of Class A common stock and Class B common stock reflect this change. Immediately prior to the completion of the IPO, the Company filed its Amended and Restated Certificate of Incorporation, which authorizes a total of 1,000,000,000 shares of Class A common stock, 100,000,000 shares of Class B common stock and 100,000,000 shares of preferred stock. During the third quarter of 2019, 484,484 shares of Class B common stock were converted to Class A common stock. As of December 31, 2019, Class A common stock and Class B common stock issued and outstanding was 20,972,166 and 75,269,430, respectively. Each share of Class A common stock is entitled to one vote per share. Each share of Class B common stock is entitled to ten votes per share and is convertible at any time into one share of Class A common stock. Basis of Presentation The consolidated financial statements, which include the Company’s accounts and the accounts of its wholly-owned subsidiaries, are prepared in accordance with U.S. generally accepted accounting principles (or “GAAP”). All intercompany transactions and balances have been eliminated. Liquidity While the Company generated positive cash flows from operations of $34.6 million for the year ended December 31, 2019, the Company has incurred significant losses and has historically had negative cash flows from operations. As of December 31, 2019, the Company had unrestricted cash and cash equivalents of $424.2 million and an accumulated deficit of $262.4 million. Management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth. The Company believes that its cash and cash equivalents balance as of December 31, 2019 provides sufficient capital resources to continue its operations for at least 12 months from the issuance date of the accompanying consolidated financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent liabilities, and the reported amounts of revenue and expense. These judgments, estimates and assumptions are used for, but not limited to, revenue recognition, inventory valuation and write-downs, loss contingencies, accounting for assets acquisitions and the valuation of stock-based compensation awards. The Company bases its estimates on various factors and information, which may include, but are not limited to, history and prior experience, the Company’s forecasts and future plans, current economic conditions and information from third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future consolidated results of operation may be affected. Segment Information The Company operates as a single operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance. Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and are stated at fair value. Restricted cash mainly represents $5.0 million of cash on deposit with a financial institution as security for a letter of credit outstanding for the benefit of the landlord related to the Company’s noncancelable operating lease for its corporate headquarters (see “—Commitments and Contingencies” below), $45.2 million of cash on deposit with a financial institution in connection with the issuance of a bond related to The 2015 Delaware Action (see “—Commitments and Contingencies” below), and $2.1 million of cash held in escrow related to royalties on certain sales pursuant to the terms of The 2015 Delaware Action. The restricted cash related to the letter of credit is classified as noncurrent restricted cash on the consolidated balance sheets based on the term of the underlying lease. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported on the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): Year Ended December 31, 2019 2018 2017 Cash and cash equivalents $ 424,166 $ 65,080 $ 47,857 Restricted cash 52,327 5,008 — Total cash, cash equivalents and restricted cash $ 476,493 $ 70,088 $ 47,857 Fair Value of Financial Instruments The Company determines the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows: Level 1: Quoted prices in active markets for identical instruments Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) Money market funds are highly liquid investments and are actively traded. The pricing information for the Company’s money market funds are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy. There were no transfers between Levels 1, 2 or 3 for any of the periods presented. As of December 31, 2019 and December 31, 2018, the Company held $398.5 million and $44.5 million in money market funds, respectively, with no unrealized gains or losses. The Company has issued common stock warrants for which fair value is determined using Level 3 inputs, see discussion in Note 8. Accounts Receivable, Net Accounts receivable consist of amounts due from customers for the sales of products and services. The Company reviews its accounts receivable and provides allowances of specific amounts if collectability is no longer reasonably assured based on historical experience and specific customer collection issues. The allowance for doubtful accounts was $0.3 million as of December 31, 2018. There was no allowance for doubtful accounts as of December 31, 2019. Business Concentrations The Company’s instruments are mostly assembled and tested by a single contract manufacturer in the United States. The Company’s agreement with the contract manufacturer expires in 2020 and may be terminated by either party for any reason by providing the other party with at least 30 days written notice. The Company’s agreement with the contract manufacturer contains purchase commitments. In addition, the Company is reliant on several suppliers for key components for its reagent kits. A significant disruption in the operations of the contract manufacturer or suppliers may impact the production of the Company’s products for a substantial period of time, which could have a material adverse effect on its business, financial condition and results of operations. Concentrations Financial instruments that potentially subject the Company to credit risk consist of cash equivalents and accounts receivable. The Company’s cash and cash equivalents are primarily held with a large financial institution in the United States and deposits exceed the Federal Deposit Insurance Corporation’s insurance limit. The Company’s debt is with this same financial institution. The Company performs periodic evaluations of the risks associated with its investments and the relative credit standing of this financial institution. The Company performs ongoing credit evaluations of its customers’ financial condition. The Company does not require collateral from its customers but may require upfront payments from certain customers. The Company has not experienced significant credit losses to date. For the years ended December 31, 2019, 2018, and 2017, no single customer represented more than 10% of revenue. As of December 31, 2019 and December 31, 2018, no single customer Substantially all the Company’s long-lived assets are located in the United States. Inventory Inventory is recorded at the lower of cost, determined on a first-in, first-out basis, Property and Equipment, Net Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method based on the estimated useful lives of the assets. Assets held under capital leases are recorded at the lower of the net present value of the minimum lease payments or the fair value of the leased assets at the inception of the lease. Amortization expense is computed using the straight-line method over the shorter of the estimated useful lives of the leased assets or the period of the related lease. Amortization of assets under capital leases is included in depreciation expense. The estimated useful lives of the Company’s property and equipment are as follows: Useful Life Laboratory equipment and machinery 3 – 5 years Computer equipment 2 – 3 years Furniture and fixtures 3 years Leasehold improvements 1 – 10 years Impairment of Long-Lived Assets The Company evaluates long-lived assets, such as property and equipment and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist and the undiscounted future cash flows that the assets are expected to generate are less than the carrying value of the assets, the Company reduces the carrying amount of the assets to their estimated fair values based on a discounted cash flow approach or, when available and appropriate, to comparable market values. There were no impairment losses recorded for the years ended December 31, 2019 and December 31, 2018. Product Warranties The Company generally provides a one-year warranty Deferred Revenue Deferred revenue consists of payments received in advance of revenue recognition primarily related to instrument service agreements, also referred to as extended warranties. Revenue under these agreements is recognized over the related service period. Deferred revenue that will be recognized during the 12 months following the balance sheet date is recorded as current portion of deferred revenue and the remaining portion is recorded as long term. Accrued Contingent Liabilities Accrued contingent liabilities represents the Company’s estimates of possible losses on pending litigation, including related accrued royalties that are both probable and reasonably estimable. See Note 7. Revenue Recognition The Company generates revenue from sales of products and services. The Company’s products consist of instruments and consumables. The revenue recognition accounting policy described below relates to revenue transactions from January 1, 2019 and onward, which are accounted for in accordance with Accounting Standards Codification Topic 606 – Revenue from Contracts with Customers The Company recognizes revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. In instances where right of payment or transfer of title is contingent upon the customer’s acceptance of the product, revenue is deferred until all acceptance criteria have been met. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year one-year The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts. The revenue recognition accounting policy described below relates to revenue transactions prior to January 1, 2019, which are accounted for in accordance with Accounting Standards Codification Topic 605 – Revenue Recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price to the customer is fixed or determinable, and collectability is reasonably assured. The Company assesses collectability based on factors such as the customer’s creditworthiness and past collection history, if applicable. If collection is not reasonably assured, revenue recognition is deferred until receipt of payment. The Company also assesses whether a price is fixed or determinable by, among other things, reviewing contractual terms and conditions related to payment. Delivery occurs when there is a transfer of title and risk of loss passes to the customer. Certain of the Company’s sales arrangements involve the delivery of multiple products and services within contractually binding arrangements. Multiple-deliverable sales transactions typically consist of the sale and delivery of one or more instruments and consumables together and may include an instrument service agreement. For sales arrangements that include multiple deliverables, the Company uses the stated contractual price for its instrument service agreements as its best estimate of selling price, if and when sold, and allocates the remaining contract consideration at the inception of the contract to the other units of accounting based upon their relative selling price. The Company may use its best estimate of selling price for individual deliverables when vendor specific objective evidence or third-party evidence is unavailable. A delivered item is considered to be a separate unit of accounting when it has value to the customer on a stand-alone basis. The Company’s products are typically delivered together or within a short time frame, generally within one to three months of the contract date. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year one-year Cost of Revenue Costs of revenue primarily consist of manufacturing costs incurred in the production process, including personnel and related costs, component materials, labor and overhead, packaging and delivery costs and allocated costs including facilities and information technology. In addition, costs of product revenue includes royalty costs for licensed technologies included in the Company’s products, warranty costs and provisions for slow-moving and obsolete inventory. In addition, beginning in November 2018, cost of revenue includes estimated accrued royalties related to the Bio-Rad Shipping and Handling Costs Shipping and handling charged to customers are recorded as revenue. Shipping and handling costs are included in the Company’s cost of revenue. Research and Development Research and development costs are expensed in the period incurred. Research and development expense consists of personnel and related costs, independent contractor costs, laboratory supplies, equipment maintenance, prototype and materials expenses, amortization of developed technology and intangibles and allocated costs including facilities and information technology. See Note 3 for discussion of in-process research Advertising Costs Advertising costs are expensed as incurred. The Company incurred advertising costs of $1.5 million, $0.7 million, and $0.2 million for the years ended December 31, 2019, 2018, and 2017, respectively. Stock-Based Compensation The Company estimates the fair value of share-based payment awards granted to employees and directors on the grant date using the Black-Scholes option-pricing model. The fair value of share-based payment awards is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. Share-based payment awards that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based awards. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield and the expected stock price volatility over the expected term. For all stock options granted, the Company calculated the expected term using the simplified method for “plain vanilla” stock option awards. The Company had no publicly available stock price information prior to its IPO and limited publicly available stock price information subsequent to its IPO and therefore, the Company has used the historical volatility of the stock price of similar publicly traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues Stock-based compensation expense for nonemployee stock options is measured based on fair market value using the Black-Scholes option pricing model and is recorded as the options vest. Prior to January 1, 2019, nonemployee stock options subject to vesting were revalued periodically over the requisite service period, which was generally the same as the vesting term of the award. From January 1, 2019, the grant date fair market value of nonemployee stock options is recognized in the consolidated statements of operations on a straight-line basis over the requisite service period and forfeitures are recognized as they occur. Foreign Currency For foreign subsidiaries where the functional currency is the local currency, assets and liabilities are translated to the U.S. dollar using month-end exchange For entities where the functional currency is the U.S. dollar, monetary assets and liabilities are remeasured using exchange rates in effect at the balance sheet dates and non-monetary assets Income Taxes The Company uses the asset and liability method of accounting for income taxes, in which deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be reversed. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that includes the enactment date. A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company’s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not (greater than 50% likely) to be realized upon settlement with the taxing authority. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in its tax provision. The Company calculates the current and deferred income tax provision based on estimates and assumptions that could differ from the actual results reflected in income tax returns filed in subsequent years. Adjustments based on filed income tax returns are recorded when identified. The amount of income tax paid is subject to examination by U.S. federal and state tax authorities. The estimate of the potential outcome of any uncertain tax issue is subject to management’s assessment of the relevant risks, facts and circumstances existing at that time. To the extent the assessment of such tax position changes, the change in estimate is recorded in the period in which the determination is made. Net Loss Per Share Net loss per share is computed using the two-class method The Company’s participating securities included the Company’s convertible preferred stock, as the holders are entitled to receive noncumulative dividends on a pari passu basis in the event that a dividend is paid on common stock. The Company also considers any shares issued on the early exercise of stock options subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. For the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities, including convertible preferred stock, awards under the Company’s equity compensation plan and common stock warrants. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding. For periods in which the Company reports net losses, diluted net loss per share is the same as basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive. Acquisitions The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the requirements of a business. The Company accounts for an asset acquisition under Accounting Standards Codification (“ASC”), Business Combinations Topic 805, Subtopic 50 the non-monetary identifiable In-process Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets. Recently Adopted Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting Compensation—Stock Compensation Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, right-of-use right-to-use In June 2016, the FASB issued ASU No. 2016-13, Credit losses (Topic 326), off-balance In August 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and Other – Internal Use Software (Subtopic 350-40) ’ s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract internal-use 350-40, In November 2019, the FASB issued ASU 2019-08, Compensation – Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606) In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740)

Asset Acquisitions

Asset Acquisitions	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Asset Acquisitions	3. Asset Acquisitions In November 2018, the Company purchased all of the outstanding shares of Spatial Transcriptomics Holdings AB (“Spatial Transcriptomics”), for $38.6 million inclusive of acquisition costs of $0.5 million. The patents acquired in this transaction will enable the Company to develop spatial products. The transaction was accounted for as an asset acquisition. In connection with this acquisition, the Company acquired patents, trademarks and customer relationships. The patents acquired were allocated a value of $36.9 million. Accordingly, the Company recognized a charge of $36.9 million related to the transaction which is included as a component of in-process Transcriptomics The following table summarizes the value of assets acquired and liabilities assumed (in thousands): Assets Acquired and Liabilities Assumed In-process $ 36,899 Intangible assets 425 Other assets and liabilities 1,237 Total net assets acquired $ 38,561 In March 2018, the Company acquired all of the outstanding shares of Epinomics Inc. (“Epinomics”) for $22.2 million inclusive of acquisition costs of $0.3 million. Of this amount, $6.2 million was due upon close of the acquisition and $16.0 million was due upon the amendment and assignment of a license agreement with the Board of Trustees of the Leland Stanford Junior University which occurred in August 2018. The technology licenses acquired in this transaction will enable the Company to develop products for epigenetics research. The transaction was accounted for as an asset acquisition. As the technology licenses acquired did not have alternative future use, the Company recognized charges of $22.2 million during the year ended December 31, 2018 related to this transaction which are included as a component of in-process

Other Financial Statement Infor

Other Financial Statement Information	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Financial Statement Information	4. Other Financial Statement Information Inventory Inventory was comprised of the following (in thousands): Year Ended December 31, 2019 2018 Purchased materials $ 6,436 $ 3,052 Work in progress 3,996 2,553 Finished goods 4,838 2,965 Inventory $ 15,270 $ 8,570 Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): Year Ended December 31, 2019 2018 Laboratory equipment and machinery $ 22,400 $ 14,616 Computer equipment 4,991 3,303 Furniture and fixtures 4,143 1,002 Leasehold improvements 33,936 3,342 Construction in progress 2,406 2,947 Total property and equipment 67,876 25,210 Less: accumulated depreciation and amortization (19,055 ) (14,083 ) Property and equipment, net $ 48,821 $ 11,127 Depreciation expense was $6.7 million, $3.8 million and $4.3 million for the years ended December 31, 2019, 2018, and 2017, respectively. Intangible Assets, Net In October 2019, as part of the 2019 Becton Dickinson Settlement and Patent Cross License Agreement with Becton, Dickinson and Company and Cellular Research, Inc. (“BD Entities”), the Company was granted a worldwide royalty-free, nonexclusive license to certain intellectual property from the BD Entities for a purchase price of $25.0 million, to be paid in annual amounts of $6.25 million over four years beginning in January 2020. The Company recognized the present value of the annual payments of $21.1 million as a liability as of the date of the agreement, which is included within accrued expenses and other current liabilities and accrued license fee. The Company recognized the estimated fair value of the license received of $22.1 million as an intangible asset which is being amortized to cost of revenue over its estimated useful life. Intangible assets, net consisted of the following (in thousands): Year Ended December 31, 2019 2018 Gross Accumulated Intangibles, Gross Accumulated Intangibles, Technology licenses $ 22,504 $ (440 ) $ 22,064 $ 379 $ (136 ) $ 243 Customer relationships 204 (32 ) 172 204 (3 ) 201 Trademarks 204 (74 ) 130 204 (6 ) 198 Total intangible assets, net $ 22,912 $ (546 ) $ 22,366 $ 787 $ (145 ) $ 642 The estimated annual amortization of intangible assets for the next five years is shown below (in thousands). Estimated 2020 $ 1,630 2021 1,625 2022 1,563 2023 1,532 2024 1,503 2025 1,500 Thereafter 13,013 Total $ 22,366 Actual amortization expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures and asset impairments, among other factors. Accrued Compensation and Related Benefits Accrued compensation and related benefits were comprised of the following (in thousands): Year Ended December 31, 2019 2018 Accrued bonus $ 6,154 $ 3,545 Accrued commissions 2,473 2,299 Other 3,767 1,203 Accrued compensation and related benefits $ 12,394 $ 7,047 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities were comprised of the following (in thousands): Year Ended December 31, 2019 2018 Accrued legal expenses $ 4,375 $ 1,769 Accrued license fee 6,183 — Accrued royalties for licensed technologies 2,025 1,571 Accrued property and equipment 3,885 990 Accrued consulting 1,173 741 Product warranties 467 804 Customer deposits 1,304 381 Taxes payable 1,087 738 Other 3,949 2,947 Accrued expenses and other current liabilities $ 24,448 $ 9,941 Product Warranties Changes in the reserve for product warranties were as follows (in thousands): Year Ended December 31, 2019 2018 Beginning of period $ 804 $ 174 Additions charged to cost of revenue 741 1,685 Repairs and replacements (1,078 ) (1,055 ) End of period $ 467 $ 804 Revenue and Deferred Revenue As of December 31, 2019, the aggregate amount of the transaction price allocated to remaining performance obligations was $4.1 million, of which approximately 80% is expected to be recognized to revenue in the next 12 months, with the remainder thereafter. These contract liabilities of $4.1 million consisted of deferred revenue related to extended warranty service agreements, and as of December 31, 2019, the short-term portion was $3.3 million. Revenue recorded during the year ended December 31, 2019 included $2.3 million of previously deferred revenue that was included in contract liabilities as of the adoption date of January 1, 2019. A summary of the change in contract liabilities is as follows (in thousands): 2019 Balance as of January 1 $ 3,497 Revenue recognized that was included in the contract liability at the beginning of the year 2,250 Revenue deferred excluding amounts recognized as revenue during the period 2,884 Balance as of December 31 $ 4,131 Contract assets as of the adoption date of January 1, 2019 and December 31, 2019 were not material. The following table represents revenue by source for the periods indicated (in thousands): Year Ended December 31, 2019 2018 2017 Instruments $ 34,945 $ 36,540 $ 24,467 Consumables 206,878 107,616 46,192 Services 4,070 2,157 426 Total revenue $ 245,893 $ 146,313 $ 71,085 The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): Year Ended December 31, 2019 2018 2017 North America $ 139,758 $ 85,132 $ 43,622 Europe, Middle East and Africa 58,004 35,812 18,602 China 29,920 15,075 3,171 Asia Pacific 18,211 10,294 5,690 Total revenue $ 245,893 $ 146,313 $ 71,085 Revenue for the United States, which is included in North America in the table above, was 54% and 55% of consolidated revenue for the years ended December 31, 2019 and 2018, respectively.

Debt

Debt	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Debt	5. Debt In September 2016, the Company entered into a loan and security Monthly payments of interest were due under the Amended Tranche A term loan through June 30, 2019, with monthly installments of principal and interest due for 42 months thereafter. If the Amended Tranche B was borrowed, monthly installments of principal and interest were to be reduced to 36 months. In June 2019, the Company's loan and security agreement was amended to extend the Company's option to borrow the Amended Tranche B through December 31, 2019. This extended period expired is is one-time The term loan may be ould s The loan and security agreement provide s is is be s In connection with the amendment of the loan and security agreement, the Company issued the lender a warrant to purchase 125,000 Class A common shares with an exercise price per share of $1.62. The warrants had an estimated fair value of $150,000 which was recorded as a debt discount. The Company had previously issued warrants to purchase an aggregate of 141,099 additional Class A common shares in connection with the loan. Thus, following the amendment of the loan and security agreement, the Company had issued warrants to purchase an aggregate of 266,099 Class A common shares. Amounts borrowed under the loan and security agreement a s may s s The term loan borrowings were prepaid in full on February 20, 2020. As of December 31, 2019 and as of February 20, 2020, the Company was in compliance with all loan covenants. Aggregate annual payments due on the term loan as of December 31, 2019, were as follows (in thousands): 2020 11,744 2021 11,055 2022 12,170 Total payments 34,969 Less: amount representing interest (4,969 ) Total term loan 30,000 Less: unamortized debt discount (281 ) Total term loan, net of debt discount 29,719 Less: current portion (9,882 ) Non-current $ 19,837

Income Tax

Income Tax	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Tax	6. Income Tax Loss before provision for income taxes were as follows for the periods indicated (in thousands): Year Ended December 31, 2019 2018 United States $ (35,675 ) $ (77,517 ) International 4,642 (34,881 ) Total $ (31,033 ) $ (112,398 ) The provision for income taxes was $0.2 million for the year ended December 31, 2019, which related to foreign and state income taxes. For the year ended December 31, 2018, the provision for income taxes was $0.1 million. A reconciliation of the federal statutory income tax provision to the effective income tax provision is as follows for the periods indicated (in thousands): Year Ended December 31, 2019 2018 Income tax provision at statutory rate $ (6,517 ) $ (23,604 ) State taxes, net (2,958 ) (4,479 ) Tax credits (2,684 ) (1,631 ) Foreign taxes 101 41 Stock-based compensation 1,032 421 Change in valuation allowance 10,783 19,133 Acquisition related expenses 116 10,143 Other 345 63 Total provision for income taxes $ 218 $ 87 Deferred income taxes reflect the net tax effect of temporary differences between amounts recorded for financial reporting purposes and amounts used for tax purposes. The major components of deferred tax assets and liabilities are as follows as of the dates indicated (in thousands): Year Ended December 31, 2019 2018 Deferred tax assets Net operating loss carryforwards $ 28,878 $ 31,031 Research and development tax credits 15,961 10,874 Accruals and reserves 23,804 12,612 Other 2,766 1,616 Total deferred tax assets 71,409 56,133 Valuation allowance (66,456 ) (55,673 ) Net deferred tax assets 4,953 460 Year Ended December 31, 2019 2018 Deferred tax liabilities Fixed assets (4,946 ) (460 ) Net deferred taxes $ 7 $ — As of December 31, 2019 and 2018, the Company maintained a full valuation allowance on its domestic net deferred tax assets. The domestic deferred tax assets predominantly relate to operating losses and tax credits. The domestic valuation allowance was estimated based on an assessment of both positive and negative evidence to determine whether it is more likely than not that deferred tax assets are recoverable. Such assessment is required on a jurisdiction-by-jurisdiction As of December 31, 2019, the Company had federal NOL carryforwards of approximately $110.7 million and federal tax credit carryforwards of approximately $12.3 million. The federal NOL carryforwards generated during and after fiscal 2018 totaling $6.5 million are carried forward indefinitely, while all others, along with the federal tax credit carryforwards, expire in years beginning in 2032. As of December 31, 2019, the Company had state net operating loss carryforwards of approximately $87 million, which begin to expire in 2032. In addition, the Company had state tax credit carryforwards of approximately $11 million, which do not expire. The federal and state net operating losses and credit carryforwards are subject to change of ownership limitations provided by the Internal Revenue Code and similar state provisions. In general, if the Company experiences a greater than 50 percentage point aggregate change in ownership over a 3-year pre-change pre-change pre-change pre-change The total balance of unrecognized gross tax benefits for the years ended December 31, 2019 and 2018 resulting primarily from research and development tax credits claimed on the Company’s annual tax returns were as follows (in thousands): 2019 2018 Unrecognized tax benefits at beginning of year $ 4,169 $ 2,692 Additions based on prior year tax provisions — 118 Additions based on current year tax provisions 2,241 1,359 Unrecognized tax benefits at end of year $ 6,410 $ 4,169 The Company has not been audited by the Internal Revenue Service or any state income tax agency. As of December 31, 2019, its federal returns for the years ended 2012 through the current period and state returns for the years ended 2012 through the current period are still open to examination. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense, in statements of comprehensive loss. In addition, all of the net operating losses and research and development credit carry-forwards that may be used in future years are still subject to inquiry given that the statute of limitation for these items would begin in the year of utilization. The Company does not expect its unrecognized tax benefits to change significantly over the next 12 months. An immaterial amount of liability related to foreign uncertain tax positions has been recorded in the Company’s consolidated financial statements. For U.S. uncertain tax positions, due to a full valuation allowance, such liabilities have been netted against deferred tax attribute carryovers. The Company maintained undistributed earnings overseas as of December 31, 2019. As of December 31, 2019, the Company believed the funds held by all non-US The Tax Cuts and Jobs Act (the “Tax Act”), was enacted on December 22, 2017. The Tax Act created a new requirement that global intangible low-taxed

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	7. Commitments and Contingencies Indemnification From time to time, the Company has entered into indemnification provisions under certain agreements in the ordinary course of business, typically with business partners, customers and suppliers. Pursuant to these agreements, the Company may indemnify, hold harmless and agree to reimburse the indemnified parties on a case-by-case Non-cancelable The Company’s contract manufacturer makes advance purchases of components based on the instrument unit forecasts and purchase orders placed by the Company. To the extent these components are purchased by the contract manufacturer on the Company’s behalf and cannot be used by their other customers, the Company is obligated to purchase these components. In addition, certain supplier agreements require that the Company make minimum annual purchases under the agreements. As of December 31, 2019, the Company has commitments to make a total of $6.4 million in purchases over the next five years. To date, the Company has met the minimum purchase commitments. As of December 31, 2019, the Company has entered into non-cancelable Intellectual Property Licensing In October 2019, as part of the 2019 Becton Dickinson Settlement and Patent Cross License Agreement with Becton, Dickinson and Company and Cellular Research, Inc. (“BD Entities”), the Company was granted a worldwide royalty-free, nonexclusive license to certain intellectual property from the BD Entities. The Company recognized $22.1 million in technology licenses as an intangible asset with a weighted average amortization period of 15 years. This license is classified within other assets on the Company’s consolidated balance sheet as of December 31, 2019. See the discussion of the 2019 Becton Dickinson Settlement and Patent Cross License Agreement below. In November 2018, the Company and Prognosys Biosciences, Inc. (“Prognosys”) entered into a license agreement pursuant to which the Company was granted an exclusive license to certain intellectual property relating to spatial analysis from Prognosys. As part of the agreement, the Company fully expensed total purchase consideration of $3.3 million comprised of cash consideration and shares of the Company’s Class A common stock. In July 2018, the Company and The Board of Trustees of the Leland Stanford Junior University (“Stanford”) entered into a license agreement pursuant to which the Company was granted an exclusive license to ATAC-seq. ATAC-seq In September 2013, the Company and the President and Fellows of Harvard College (“Harvard”) entered into a license agreement pursuant to which the Company was granted a license to certain intellectual property from Harvard. The Company is required to pay Harvard a low single-digit royalty percentage based on the net revenue of certain products covered by certain licensed patents during their applicable term. The minimum commitments related to the above license arrangements aggregate to $4.9 million as of December 31, 2019 to be paid over the next 14 years. Leases The Company leases its facilities under noncancelable lease agreements. Certain of these arrangements have free rent, escalating rent payment provisions and tenant allowances. Under such arrangements, the Company recognizes rent expense on a straight-line basis over the noncancelable lease term and records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability within other current liabilities (current portion) and other liabilities (noncurrent portion). The Company maintains a letter of credit for the benefit of the landlord related to the Company’s noncancelable operating lease for its corporate headquarters in the amount of $5.0 million. Rent expense related to noncancelable operating leases was $6.8 million, $3.5 million and $1.0 million for the years ended December 31, 2019, 2018 and 2017, respectively. Future minimum lease payments under the leases for facilities as of December 31, 2019, are as follows (in thousands): Operating 2020 $ 6,247 2021 7,581 2022 6,794 2023 6,947 2024 and thereafter 45,410 Total future minimum lease commitments $ 72,979 Litigation The Company is currently a defendant in the lawsuits and proceedings described below. Other than with respect to the 2015 Delaware Action, losses are not probable or estimable for the described below. The 2015 Delaware Action In February 2015, Raindance Technologies, Inc. (“Raindance”) and the University of Chicago filed suit against the Company in the U.S. District Court for the District of Delaware, accusing substantially all of the Company’s products of infringing certain patents. In May 2017, Bio-Rad (“Bio-Rad”) Bio-Rad Bio-Rad pre- In response to the jury award, the Company established an accrual of $30.6 million as of December 31, 2018, which was recorded as an operating expense on the consolidated statement of operations for the year ended December 31, 2018. Additionally, beginning in the fourth quarter of 2018, the Company also began recording an accrual for estimated royalties to Bio-Rad In July 2019, the Court awarded supplemental damages for the period from June 30, 2018 through the end of the trial in November 2018 and established the interest rates for pre- Bio-Rad pre-and Bio-Rad’s In July 2019, the Court also granted Bio-Rad Bio-Rad , which will hold oral arguments In August 2019, the Court ordered that the Company may post a bond in the amount of $52 million in lieu of payment of the final judgment. Bio-Rad On October 10, 2019, the Court denied the Company’s motion to decrease the bond amount, and, without addressing Bio-Rad’s The ITC 1068 Action On July 31, 2017, Bio-Rad On December 18, 2019, the ITC issued its final determination in the ITC 1068 Action (the “Final Determination”). The Final Determination affirmed the Initial Determination that the Company’s Next GEM microfluidic chips and gel bead manufacturing microfluidic chips do not infringe any of the claims asserted against them. The Final Determination also affirmed the ruling that the Company’s GEM microfluidic chips infringe the ‘664, ‘682 and ‘635 patents but not the ‘160 patent. The ITC issued (1) a limited exclusion order prohibiting the unlicensed importation of the GEM microfluidic chips into the United States and (2) a cease and desist order preventing the Company from selling such imported GEM microfluidic chips in the United States. The ITC expressly allowed the importation and sale of the GEM microfluidic chips for use by researchers who were using such chips as of December 18, 2019, and who have a documented need to continue receiving such chips for a specific current ongoing research project for which that need cannot be met by any alternative product. The Final Determination was subject to a 60-day The Northern District of California Action On July 31, 2017, Bio-Rad The Germany Action On July 31, 2017, Bio-Rad Bio-Rad On February 13, 2018, Bio-Rad Bio-Rad Bio-Rad The Company has accrued the 61,000 Euros in statutory costs in the consolidated balance sheet as of December 31, 2019. The Company is unable to estimate any additional potential exposure related to the matter beyond the statutory costs that have been accrued. The remedies, including the injunction, will take effect once enforced upon the posting of a bond by Bio-Rad. The 2018 Delaware Action On October 25, 2018, Bio-Rad Bio-Rad The Massachusetts Action On September 11, 2019, Bio-Rad Bio-Rad Bio-Rad subsequently joined On December 18, 2019, Bio-Rad Bio-Rad Bio-Rad On January 24, 2020, the Company filed antitrust counterclaims against Bio-Rad analysis technology. On February 19, 2020, Bio-Rad moved to dismiss, or alternatively to stay and sever, the Company’s antitrust claims. A hearing on Bio-Rad’s motion to dismiss is scheduled in March 2020 On February 5, the Company filed additional counterclaims against Bio-Rad Bio-Rad’s ATAC-seq A Markman hearing has been scheduled in June 2020. The judge has ordered the parties to be ready for trial with respect to the Company’s antitrust counterclaims by April 2021. A trial date for Bio-Rad’s for The 2019 Becton Dickinson Settlement and Patent Cross License Agreement On November 15, 2018, Becton, Dickinson and Company (“BD”) and Cellular Research, Inc. filed suit against the Company in the U.S. District Court for the District of Delaware, alleging that the Company infringed certain patents. In September 2019, the Company filed counterclaims alleging that BD and Cellular Research, Inc. (together, the “BD Entities”) infringed a number of the Company’s patents. In October 2019, the Company entered into a settlement and patent cross license agreement (the “BD Agreement”) with the BD Entities. The BD Agreement resolved all outstanding patent litigation between the parties (the “BD Litigation”), which was dismissed with prejudice on October 21, 2019. Under the terms of the BD Agreement, the BD Entities granted the Company and its affiliates, and the Company granted BD and its affiliates, a worldwide, royalty-free, non-exclusive, fully paid-up license For certain of the Company’s litigation matters, the Company is required to make milestone payments to the Company’s legal counsel based on certain litigation outcomes. Based on the occurrence in the first quarter of 2020 of one such milestone in one of the Company’s litigation matters, a milestone payment to the Company’s legal counsel in the amount of $5 million was triggered in the first quarter of 2020. The Company expects to trigger additional such milestone payments during the pendency of litigation, though the timing and amounts of such payments is uncertain.

Capital Stock and Stockholders'

Capital Stock and Stockholders' Deficit	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Capital Stock and Stockholders' Deficit	8. Capital Stock and Stockholders’ Deficit The Company’s Amended and Restated Certificate of Incorporation authorizes it to issue 1,200,000,000 shares of capital stock consisting of 1,000,000,000 shares of Class A common stock, 100,000,000 shares of Class B common stock, and 100,000,000 shares of convertible preferred stock. Common Stock Common stock issued and outstanding was 96,241,596 and 14,549,801 as of December 31, 2019 and 2018, respectively. Class A common stock outstanding was 20,972,166 and 6,499,801 as of December 31, 2019 and 2018, respectively. Class B common stock outstanding was 75,269,430 and 8,050,000 as of December 31, 2019 and 2018, respectively. The Company’s Class A common stock and Class B common stock have a par value of $0.00001 per share. Each share of Class B common stock has the right to ten votes and each share of Class A common stock has the right to one vote per share. All other rights and privileges of Class A and Class B common stock are equivalent. Class B common shares are convertible to Class A common shares at any time upon written notification and all Class B common shares will convert upon the date specified by vote or written consent of the holders of a majority of the then outstanding Class B common stock, voting together as a single class. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. Warrants to Purchase Common Stock In connection with certain debt arrangements, the Company issued lenders the following warrants to purchase shares of Class A common stock which have an exercise term of 10 years: Issue Date Exercise Price Number April 2014 $ 0.21 43,750 September 2015 0.88 18,349 September 2016 1.07 79,000 February 2018 1.62 125,000 In September 2019, the lenders cashless exercised all of the above warrants which resulted in the issuance of an aggregate of 261,024 shares of common stock. The Company’s common stock warrants were recorded to additional paid-in

Equity Incentive Plans

Equity Incentive Plans	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Equity Incentive Plans	9. Equity Incentive Plans 2012 Stock Plan In October 2012, the Company adopted the 10x Genomics, Inc. 2012 Stock Plan (the “2012 Stock Plan”) which has been amended in subsequent years for increases in authorized shares, among other changes. The 2012 Stock Plan allowed for the issuance of incentive stock options (“ISOs”), non-statutory Upon the adoption of the 2019 Omnibus Incentive Plan in September 2019, any awards outstanding under the 2012 Stock Plan will continue to be governed by their existing terms but no further awards may be granted under the 2012 Stock Plan. 2019 Omnibus Incentive Plan In July 2019, in connection with the IPO, the Company’s board of directors adopted the 10x Genomics, Inc. 2019 Omnibus Incentive Plan (the “Omnibus Incentive Plan” and, together with the 2012 Stock Plan, the “Plans”), which was subsequently approved by the Company’s stockholders. The Omnibus Incentive Plan went into effect on September 11, 2019. The Omnibus Incentive Plan allows for the issuance of ISOs, NSOs or restricted shares. ISOs may be granted only to the Company’s employees (including officers and directors who are also considered employees). NSOs and restricted shares may be granted to the Company’s employees and service providers. As of December 31, 2019, the number of shares of Class A common stock issuable upon the exercise of stock options granted under the Omnibus Incentive Plan is 11,000,000. The Omnibus Incentive Plan provides that the total number of shares of the Company’s Class A common stock that may be issued under the Omnibus Incentive Plan, including options authorized and options outstanding, is 11,000,000 (such share limit as increased from time to time, the “Absolute Share Limit”). However, the Absolute Share Limit shall be increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 5% of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year, the Company’s board of directors has not either confirmed the 5% increase described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, then the Company’s board of directors will be deemed to have waived the automatic increase, and no such increase will occur for such calendar year. Of the Absolute Share Limit, no more than 11,000,000 shares of Class A common stock may be issued in the aggregate pursuant to the exercise of incentive stock options granted under the Omnibus Incentive Plan. Options under the Omnibus Incentive Plan have a contractual term of 10 years. The exercise price of an ISO and NSO shall not be less than 100% of the fair market value of the shares on the date of grant. A summary of the Company’s stock option activity under the Plans is as follows: Outstanding Weighted- Weighted- Aggregate Balance as of December 31, 2018 14,264,376 $ 1.91 8.2 $ 71,902,234 Granted 4,785,842 $ 19.05 Exercised (2,226,493 ) $ 1.69 Cancelled (905,482 ) $ 6.71 Balance as of December 31, 2019 15,918,243 $ 6.82 7.9 $ 1,105,222,370 Outstanding Weighted- Weighted- Aggregate Vested and exercisable as of December 31, 2019 7,362,304 $ 1.96 6.9 $ 546,973,399 Unvested and exercisable as of December 31, 2019 1,138,439 $ 5.90 8.3 $ 80,094,346 The weighted-average grant date fair value of options granted during the years ended December 31, 2019, 2018, and 2017 was $13.20, $2.04, and $0.66 per share, respectively. The total intrinsic value of stock options exercised was $30.5 million, $3.3 million, and $0.8 million during the years ended December 31, 2019, 2018, and 2017, respectively. As of December 31, 2019, the total unrecognized stock-based compensation related to stock options was $57.8 million, which will be recognized over a weighted-average period of approximately 3.2 years. Early Exercise of Options Stock options granted under the 2012 Stock Plan provide certain employee and director option holders the right to exercise unvested options in exchange for restricted shares of Class A common stock which are subject to repurchase by the Company at the original issuance price in the event the optionee’s employment is terminated either voluntarily or involuntarily prior to the applicable vesting date. The consideration received for the early exercised options is recorded as a liability on the consolidated balance sheets and reclassified to stockholders’ deficit as the shares vest. As of December 31, 2019 and 2018, the total repurchase liability related to the unvested early exercised options was $494,000 and $652,000, respectively, which is included in other current and noncurrent liabilities on the consolidated balance sheets. A summary of these restricted shares issued under the 2012 Stock Plan is as follows: Number of Shares Weighted- Average Outstanding and unvested as of December 31, 2018 232,750 $ 2.80 Exercised 29,000 $ 11.48 Vested (123,500 ) $ 3.98 Outstanding and unvested as of December 31, 2019 138,250 $ 3.57 Stock Option Valuation Assumptions The fair value of each employee option grant was estimated on the date of grant using the Black-Scholes option pricing model and the following assumptions for the periods indicated: Year Ended December 31, 2019 2018 2017 Expected volatility 40% – 53% 45% – 46% 45% – 48% Risk-free interest rate 1.5% – 2.5% 2.7% – 3.1% 1.9% – 2.3% Expected term 5.0 – 6.9 years 5.3 – 6.5 years 4.2 – 6.5 years Expected dividend — % — % — % 2019 Employee Stock Purchase Plan In July 2019, the Company’s board of directors adopted the 10x Genomics, Inc. 2019 Employee Stock Purchase Plan (the “ESPP”), which was subsequently approved by the Company’s stockholders. The ESPP went into effect on September 11, 2019. Subject to any limitations contained therein, the ESPP allows eligible employees to contribute, through payroll deductions, up to 15% of their eligible compensation to purchase the Company’s Class A common stock at a discounted price per share. The ESPP generally provides for consecutive, overlapping 6-month offering the Company’s Class A total of 2,000,000 shares of Class A common stock were reserved for issuance under the ESPP. As of December 31, 2019, no shares of Class A common stock have been purchased under the ESPP. The ESPP provides that the maximum number of shares of the Company’s Class A common stock made available for sale thereunder will be 2,000,000, which number will be automatically increased on the first day of each calendar year commencing on January 1, 2021 and ending on January 1, 2029 in an amount equal to the lesser of (i) 1% of the total number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) such number of shares of the Company’s Class A common stock as determined by the Company’s board of directors. However, if on January 1 of a calendar year the Company’s board of directors has not either confirmed the 1% described in clause (i) or approved a lesser number of shares of the Company’s Class A common stock for such calendar year, the Company’s board of directors will be deemed to have waived the automatic increase and no such increase will occur for such calendar year. The maximum number of shares available under the ESPP (and any share limitations thereunder, as applicable) will automatically be adjusted upon certain changes to the Company’s capital structure. The fair value of the ESPP is estimated using the Black-Scholes option pricing model. For the year ended December 31, 2019, the grant date fair value was $12.60. For the year ended December 31, 2019, the fair value of the ESPP was estimated using the following assumptions. Year Ended December 31, 2019 Expected volatility 52% Risk-free interest rate 1.85% Expected term 0.7 years Expected dividend — % The ESPP commenced in September 2019. No shares of common stock were purchased pursuant to the ESPP in 2019. As of December 31, 2019, the total unrecognized stock-based compensation related to the ESPP was $1.0 million, which will be recognized over a weighted-average period of approximately 0.4 years. Stock-based Compensation The Company recorded stock-based compensation expense in the consolidated statement of operations for the periods presented as follows (in thousands): Year Ended December 31, 2019 2018 2017 Cost of revenue $ 325 $ 85 $ 44 Research and development 5,721 1,030 801 Selling, general and administrative 7,287 1,543 816 Total stock-based compensation expense $ 13,333 $ 2,658 $ 1,661

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2019
Retirement Benefits [Abstract]
Summary of Employee Benefit Plans	10. Employee Benefit Plans The Company has made available to all full-time United States employees a 401(k) retirement savings plan. Under this plan, employee and employer contributions and accumulated plan earnings qualify for favorable tax treatment under Section 401(k) of the Internal Revenue Code. The Company has not contributed to the plan.

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Net Loss Per Share	11. Net Loss Per Share The following table sets forth the computation of basic and diluted net loss per share for the periods indicated (in thousands, except share and per share data): Year Ended December 31, 2019 2018 2017 Net loss $ (31,251 ) $ (112,485 ) $ (18,762 ) Weighted average shares used in computing net loss per share, basic and diluted 39,091,366 13,392,273 11,587,751 Net loss per share, basic and diluted $ (0.80 ) $ (8.40 ) $ (1.62 ) The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Year Ended December 31, 2019 2018 2017 Convertible preferred stock (on an if-converted — 67,704,278 59,730,213 Stock-options to purchase common stock 15,918,243 14,264,376 11,949,004 Shares subject to repurchase 138,250 232,750 301,372 Common stock warrants — 266,099 141,099 Shares committed under ESPP 56,159 — — Total 16,112,652 82,467,503 72,121,688

Selected Quarterly Information

Selected Quarterly Information	12 Months Ended
	Dec. 31, 2019
Selected Quarterly Financial Information [Abstract]
Selected Quarterly Information	12. Selected Quarterly Information The following tables present certain unaudited consolidated quarterly financial information for each of the eight quarters in the two-year Fiscal 2019 Quarter Ended (Unaudited) March 31 June 30 September 30 December 31 (in thousands, except per share data) Revenue $ 53,578 $ 55,819 $ 61,207 $ 75,289 Gross profit $ 39,613 $ 40,813 $ 45,727 $ 58,707 Net loss $ (3,636 ) $ (10,878 ) $ (9,603 ) $ (7,134 ) Net loss per share, basic and diluted $ (0.25 ) $ (0.70 ) $ (0.33 ) $ (0.07 ) Fiscal 2018 Quarter Ended (Unaudited) March 31 June 30 September 30 December 31 (in thousands, except per share data) Revenue $ 27,408 $ 31,744 $ 36,607 $ 50,554 Gross profit $ 23,438 $ 27,194 $ 31,366 $ 35,654 Net loss $ (15,693 ) $ (5,923 ) $ (15,345 ) $ (75,524 ) Net loss per share, basic and diluted $ (1.23 ) $ (0.45 ) $ (1.13 ) $ (5.40 )

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events On February 20, 2020, the term loan borrowings were prepaid in full. See Note 5.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent liabilities, and the reported amounts of revenue and expense. These judgments, estimates and assumptions are used for, but not limited to, revenue recognition, inventory valuation and write-downs, loss contingencies, accounting for assets acquisitions and the valuation of stock-based compensation awards. The Company bases its estimates on various factors and information, which may include, but are not limited to, history and prior experience, the Company’s forecasts and future plans, current economic conditions and information from third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future consolidated results of operation may be affected.
Segment Information	Segment Information The Company operates as a single operating segment. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources, making operating decisions and evaluating financial performance.
Cash Equivalents and Restricted Cash	Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market funds and are stated at fair value. Restricted cash mainly represents $5.0 million of cash on deposit with a financial institution as security for a letter of credit outstanding for the benefit of the landlord related to the Company’s noncancelable operating lease for its corporate headquarters (see “—Commitments and Contingencies” below), $45.2 million of cash on deposit with a financial institution in connection with the issuance of a bond related to The 2015 Delaware Action (see “—Commitments and Contingencies” below), and $2.1 million of cash held in escrow related to royalties on certain sales pursuant to the terms of The 2015 Delaware Action. The restricted cash related to the letter of credit is classified as noncurrent restricted cash on the consolidated balance sheets based on the term of the underlying lease. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported on the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): Year Ended December 31, 2019 2018 2017 Cash and cash equivalents $ 424,166 $ 65,080 $ 47,857 Restricted cash 52,327 5,008 — Total cash, cash equivalents and restricted cash $ 476,493 $ 70,088 $ 47,857
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company determines the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows: Level 1: Quoted prices in active markets for identical instruments Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) Money market funds are highly liquid investments and are actively traded. The pricing information for the Company’s money market funds are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy. There were no transfers between Levels 1, 2 or 3 for any of the periods presented. As of December 31, 2019 and December 31, 2018, the Company held $398.5 million and $44.5 million in money market funds, respectively, with no unrealized gains or losses. The Company has issued common stock warrants for which fair value is determined using Level 3 inputs, see discussion in Note 8.
Accounts Receivable, Net	Accounts Receivable, Net Accounts receivable consist of amounts due from customers for the sales of products and services. The Company reviews its accounts receivable and provides allowances of specific amounts if collectability is no longer reasonably assured based on historical experience and specific customer collection issues. The allowance for doubtful accounts was $0.3 million as of December 31, 2018. There was no allowance for doubtful accounts as of December 31, 2019.
Business Concentrations	Business Concentrations The Company’s instruments are mostly assembled and tested by a single contract manufacturer in the United States. The Company’s agreement with the contract manufacturer expires in 2020 and may be terminated by either party for any reason by providing the other party with at least 30 days written notice. The Company’s agreement with the contract manufacturer contains purchase commitments. In addition, the Company is reliant on several suppliers for key components for its reagent kits. A significant disruption in the operations of the contract manufacturer or suppliers may impact the production of the Company’s products for a substantial period of time, which could have a material adverse effect on its business, financial condition and results of operations.
Concentrations	Concentrations Financial instruments that potentially subject the Company to credit risk consist of cash equivalents and accounts receivable. The Company’s cash and cash equivalents are primarily held with a large financial institution in the United States and deposits exceed the Federal Deposit Insurance Corporation’s insurance limit. The Company’s debt is with this same financial institution. The Company performs periodic evaluations of the risks associated with its investments and the relative credit standing of this financial institution. The Company performs ongoing credit evaluations of its customers’ financial condition. The Company does not require collateral from its customers but may require upfront payments from certain customers. The Company has not experienced significant credit losses to date. For the years ended December 31, 2019, 2018, and 2017, no single customer represented more than 10% of revenue. As of December 31, 2019 and December 31, 2018, no single customer Substantially all the Company’s long-lived assets are located in the United States.
Inventory	Inventory Inventory is recorded at the lower of cost, determined on a first-in, first-out basis,
Property and Equipment, Net	Property and Equipment, Net Property and equipment, net is stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method based on the estimated useful lives of the assets. Assets held under capital leases are recorded at the lower of the net present value of the minimum lease payments or the fair value of the leased assets at the inception of the lease. Amortization expense is computed using the straight-line method over the shorter of the estimated useful lives of the leased assets or the period of the related lease. Amortization of assets under capital leases is included in depreciation expense. The estimated useful lives of the Company’s property and equipment are as follows: Useful Life Laboratory equipment and machinery 3 – 5 years Computer equipment 2 – 3 years Furniture and fixtures 3 years Leasehold improvements 1 – 10 years
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates long-lived assets, such as property and equipment and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment exist and the undiscounted future cash flows that the assets are expected to generate are less than the carrying value of the assets, the Company reduces the carrying amount of the assets to their estimated fair values based on a discounted cash flow approach or, when available and appropriate, to comparable market values. There were no impairment losses recorded for the years ended December 31, 2019 and December 31, 2018.
Product Warranties	Product Warranties The Company generally provides a one-year warranty
Deferred Revenue	Deferred Revenue Deferred revenue consists of payments received in advance of revenue recognition primarily related to instrument service agreements, also referred to as extended warranties. Revenue under these agreements is recognized over the related service period. Deferred revenue that will be recognized during the 12 months following the balance sheet date is recorded as current portion of deferred revenue and the remaining portion is recorded as long term.
Accrued Contingent Liabilities	Accrued Contingent Liabilities Accrued contingent liabilities represents the Company’s estimates of possible losses on pending litigation, including related accrued royalties that are both probable and reasonably estimable. See Note 7.
Revenue Recognition	Revenue Recognition The Company generates revenue from sales of products and services. The Company’s products consist of instruments and consumables. The revenue recognition accounting policy described below relates to revenue transactions from January 1, 2019 and onward, which are accounted for in accordance with Accounting Standards Codification Topic 606 – Revenue from Contracts with Customers The Company recognizes revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. Revenue from product sales is recognized when control of the product is transferred, which is generally upon shipment to the customer. In instances where right of payment or transfer of title is contingent upon the customer’s acceptance of the product, revenue is deferred until all acceptance criteria have been met. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year one-year The Company regularly enters into contracts that include various combinations of products and services which are generally distinct and accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. The Company determines standalone selling price using average selling prices with consideration of current market conditions. If the product or service has no history of sales or if the sales volume is not sufficient, the Company relies upon prices set by management, adjusted for applicable discounts. The revenue recognition accounting policy described below relates to revenue transactions prior to January 1, 2019, which are accounted for in accordance with Accounting Standards Codification Topic 605 – Revenue Recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price to the customer is fixed or determinable, and collectability is reasonably assured. The Company assesses collectability based on factors such as the customer’s creditworthiness and past collection history, if applicable. If collection is not reasonably assured, revenue recognition is deferred until receipt of payment. The Company also assesses whether a price is fixed or determinable by, among other things, reviewing contractual terms and conditions related to payment. Delivery occurs when there is a transfer of title and risk of loss passes to the customer. Certain of the Company’s sales arrangements involve the delivery of multiple products and services within contractually binding arrangements. Multiple-deliverable sales transactions typically consist of the sale and delivery of one or more instruments and consumables together and may include an instrument service agreement. For sales arrangements that include multiple deliverables, the Company uses the stated contractual price for its instrument service agreements as its best estimate of selling price, if and when sold, and allocates the remaining contract consideration at the inception of the contract to the other units of accounting based upon their relative selling price. The Company may use its best estimate of selling price for individual deliverables when vendor specific objective evidence or third-party evidence is unavailable. A delivered item is considered to be a separate unit of accounting when it has value to the customer on a stand-alone basis. The Company’s products are typically delivered together or within a short time frame, generally within one to three months of the contract date. Instrument service agreements, which relate to extended warranties, are typically entered into for one-year one-year
Cost of Revenue	Cost of Revenue Costs of revenue primarily consist of manufacturing costs incurred in the production process, including personnel and related costs, component materials, labor and overhead, packaging and delivery costs and allocated costs including facilities and information technology. In addition, costs of product revenue includes royalty costs for licensed technologies included in the Company’s products, warranty costs and provisions for slow-moving and obsolete inventory. In addition, beginning in November 2018, cost of revenue includes estimated accrued royalties related to the Bio-Rad
Shipping and Handling Costs	Shipping and Handling Costs Shipping and handling charged to customers are recorded as revenue. Shipping and handling costs are included in the Company’s cost of revenue.
Research and Development	Research and Development Research and development costs are expensed in the period incurred. Research and development expense consists of personnel and related costs, independent contractor costs, laboratory supplies, equipment maintenance, prototype and materials expenses, amortization of developed technology and intangibles and allocated costs including facilities and information technology. See Note 3 for discussion of in-process research
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred. The Company incurred advertising costs of $1.5 million, $0.7 million, and $0.2 million for the years ended December 31, 2019, 2018, and 2017, respectively.
Stock-Based Compensation	Stock-Based Compensation The Company estimates the fair value of share-based payment awards granted to employees and directors on the grant date using the Black-Scholes option-pricing model. The fair value of share-based payment awards is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. Share-based payment awards that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based awards. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield and the expected stock price volatility over the expected term. For all stock options granted, the Company calculated the expected term using the simplified method for “plain vanilla” stock option awards. The Company had no publicly available stock price information prior to its IPO and limited publicly available stock price information subsequent to its IPO and therefore, the Company has used the historical volatility of the stock price of similar publicly traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues Stock-based compensation expense for nonemployee stock options is measured based on fair market value using the Black-Scholes option pricing model and is recorded as the options vest. Prior to January 1, 2019, nonemployee stock options subject to vesting were revalued periodically over the requisite service period, which was generally the same as the vesting term of the award. From January 1, 2019, the grant date fair market value of nonemployee stock options is recognized in the consolidated statements of operations on a straight-line basis over the requisite service period and forfeitures are recognized as they occur.
Foreign Currency	Foreign Currency For foreign subsidiaries where the functional currency is the local currency, assets and liabilities are translated to the U.S. dollar using month-end exchange For entities where the functional currency is the U.S. dollar, monetary assets and liabilities are remeasured using exchange rates in effect at the balance sheet dates and non-monetary assets
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for income taxes, in which deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be reversed. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that includes the enactment date. A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company’s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not (greater than 50% likely) to be realized upon settlement with the taxing authority. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in its tax provision. The Company calculates the current and deferred income tax provision based on estimates and assumptions that could differ from the actual results reflected in income tax returns filed in subsequent years. Adjustments based on filed income tax returns are recorded when identified. The amount of income tax paid is subject to examination by U.S. federal and state tax authorities. The estimate of the potential outcome of any uncertain tax issue is subject to management’s assessment of the relevant risks, facts and circumstances existing at that time. To the extent the assessment of such tax position changes, the change in estimate is recorded in the period in which the determination is made.
Net Loss Per Share	Net Loss Per Share Net loss per share is computed using the two-class method The Company’s participating securities included the Company’s convertible preferred stock, as the holders are entitled to receive noncumulative dividends on a pari passu basis in the event that a dividend is paid on common stock. The Company also considers any shares issued on the early exercise of stock options subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. For the calculation of diluted net loss per share, basic net loss per share is adjusted by the effect of dilutive securities, including convertible preferred stock, awards under the Company’s equity compensation plan and common stock warrants. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding. For periods in which the Company reports net losses, diluted net loss per share is the same as basic net loss per share because potentially dilutive shares of common stock are not assumed to have been issued if their effect is anti-dilutive.
Acquisitions	Acquisitions The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the requirements of a business. The Company accounts for an asset acquisition under Accounting Standards Codification (“ASC”), Business Combinations Topic 805, Subtopic 50 the non-monetary identifiable In-process Contingent consideration payments in asset acquisitions are recognized when the contingency is resolved and the consideration is paid or becomes payable (unless the contingent consideration meets the definition of a derivative, in which case the amount becomes part of the basis in the asset acquired). Upon recognition of the contingent consideration payment, the amount is included in the cost of the acquired asset or group of assets.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting Compensation—Stock Compensation
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, right-of-use right-to-use In June 2016, the FASB issued ASU No. 2016-13, Credit losses (Topic 326), off-balance In August 2018, the FASB issued ASU 2018-15, Intangibles – Goodwill and Other – Internal Use Software (Subtopic 350-40) ’ s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract internal-use 350-40, In November 2019, the FASB issued ASU 2019-08, Compensation – Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606) In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Cash equivalents and restricted cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported on the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands): Year Ended December 31, 2019 2018 2017 Cash and cash equivalents $ 424,166 $ 65,080 $ 47,857 Restricted cash 52,327 5,008 — Total cash, cash equivalents and restricted cash $ 476,493 $ 70,088 $ 47,857
Property and Equipment, Net	The estimated useful lives of the Company’s property and equipment are as follows: Useful Life Laboratory equipment and machinery 3 – 5 years Computer equipment 2 – 3 years Furniture and fixtures 3 years Leasehold improvements 1 – 10 years

Asset Acquisitions (Tables)

Asset Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Summary of assets acquired and liabilities assumed	The following table summarizes the value of assets acquired and liabilities assumed (in thousands): Assets Acquired and Liabilities Assumed In-process $ 36,899 Intangible assets 425 Other assets and liabilities 1,237 Total net assets acquired $ 38,561

Other Financial Statement Inf_2

Other Financial Statement Information (Tables)	12 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of inventory	Inventory was comprised of the following (in thousands): Year Ended December 31, 2019 2018 Purchased materials $ 6,436 $ 3,052 Work in progress 3,996 2,553 Finished goods 4,838 2,965 Inventory $ 15,270 $ 8,570
Schedule of property plant and equipment	Property and equipment, net consisted of the following (in thousands): Year Ended December 31, 2019 2018 Laboratory equipment and machinery $ 22,400 $ 14,616 Computer equipment 4,991 3,303 Furniture and fixtures 4,143 1,002 Leasehold improvements 33,936 3,342 Construction in progress 2,406 2,947 Total property and equipment 67,876 25,210 Less: accumulated depreciation and amortization (19,055 ) (14,083 ) Property and equipment, net $ 48,821 $ 11,127
Schedule of Intangible assets net	Intangible assets, net consisted of the following (in thousands): Year Ended December 31, 2019 2018 Gross Accumulated Intangibles, Gross Accumulated Intangibles, Technology licenses $ 22,504 $ (440 ) $ 22,064 $ 379 $ (136 ) $ 243 Customer relationships 204 (32 ) 172 204 (3 ) 201 Trademarks 204 (74 ) 130 204 (6 ) 198 Total intangible assets, net $ 22,912 $ (546 ) $ 22,366 $ 787 $ (145 ) $ 642
Schedule of accrued compensation and related benefits	Accrued compensation and related benefits were comprised of the following (in thousands): Year Ended December 31, 2019 2018 Accrued bonus $ 6,154 $ 3,545 Accrued commissions 2,473 2,299 Other 3,767 1,203 Accrued compensation and related benefits $ 12,394 $ 7,047
Schedule of annual amortization of intangible assets	The estimated annual amortization of intangible assets for the next five years is shown below (in thousands). Estimated 2020 $ 1,630 2021 1,625 2022 1,563 2023 1,532 2024 1,503 2025 1,500 Thereafter 13,013 Total $ 22,366
Schedule of accrued expense And other current liabilities	Accrued expenses and other current liabilities were comprised of the following (in thousands): Year Ended December 31, 2019 2018 Accrued legal expenses $ 4,375 $ 1,769 Accrued license fee 6,183 — Accrued royalties for licensed technologies 2,025 1,571 Accrued property and equipment 3,885 990 Accrued consulting 1,173 741 Product warranties 467 804 Customer deposits 1,304 381 Taxes payable 1,087 738 Other 3,949 2,947 Accrued expenses and other current liabilities $ 24,448 $ 9,941
Schedule of changes in the reserve for product warranties	Changes in the reserve for product warranties were as follows (in thousands): Year Ended December 31, 2019 2018 Beginning of period $ 804 $ 174 Additions charged to cost of revenue 741 1,685 Repairs and replacements (1,078 ) (1,055 ) End of period $ 467 $ 804
ChangeInContractWithCustomerAssetAndLiabilityAbstract	A summary of the change in contract liabilities is as follows (in thousands): 2019 Balance as of January 1 $ 3,497 Revenue recognized that was included in the contract liability at the beginning of the year 2,250 Revenue deferred excluding amounts recognized as revenue during the period 2,884 Balance as of December 31 $ 4,131
Schedule of revenue by source	The following table represents revenue by source for the periods indicated (in thousands): Year Ended December 31, 2019 2018 2017 Instruments $ 34,945 $ 36,540 $ 24,467 Consumables 206,878 107,616 46,192 Services 4,070 2,157 426 Total revenue $ 245,893 $ 146,313 $ 71,085
Schedule of revenue by geography	The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands): Year Ended December 31, 2019 2018 2017 North America $ 139,758 $ 85,132 $ 43,622 Europe, Middle East and Africa 58,004 35,812 18,602 China 29,920 15,075 3,171 Asia Pacific 18,211 10,294 5,690 Total revenue $ 245,893 $ 146,313 $ 71,085

Debt - (Tables)

Debt - (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Summary of Aggregate annual payments due on the term loan	Aggregate annual payments due on the term loan as of December 31, 2019, were as follows (in thousands): 2020 11,744 2021 11,055 2022 12,170 Total payments 34,969 Less: amount representing interest (4,969 ) Total term loan 30,000 Less: unamortized debt discount (281 ) Total term loan, net of debt discount 29,719 Less: current portion (9,882 ) Non-current $ 19,837

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	Loss before provision for income taxes were as follows for the periods indicated (in thousands): Year Ended December 31, 2019 2018 United States $ (35,675 ) $ (77,517 ) International 4,642 (34,881 ) Total $ (31,033 ) $ (112,398 )
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the federal statutory income tax provision to the effective income tax provision is as follows for the periods indicated (in thousands): Year Ended December 31, 2019 2018 Income tax provision at statutory rate $ (6,517 ) $ (23,604 ) State taxes, net (2,958 ) (4,479 ) Tax credits (2,684 ) (1,631 ) Foreign taxes 101 41 Stock-based compensation 1,032 421 Change in valuation allowance 10,783 19,133 Acquisition related expenses 116 10,143 Other 345 63 Total provision for income taxes $ 218 $ 87
ScheduleOfDeferredTaxAssetsAndLiabilities	The major components of deferred tax assets and liabilities are as follows as of the dates indicated (in thousands): Year Ended December 31, 2019 2018 Deferred tax assets Net operating loss carryforwards $ 28,878 $ 31,031 Research and development tax credits 15,961 10,874 Accruals and reserves 23,804 12,612 Other 2,766 1,616 Total deferred tax assets 71,409 56,133 Valuation allowance (66,456 ) (55,673 ) Net deferred tax assets 4,953 460 Year Ended December 31, 2019 2018 Deferred tax liabilities Fixed assets (4,946 ) (460 ) Net deferred taxes $ 7 $ —
Summary of Income Tax Contingencies	The total balance of unrecognized gross tax benefits for the years ended December 31, 2019 and 2018 resulting primarily from research and development tax credits claimed on the Company’s annual tax returns were as follows (in thousands): 2019 2018 Unrecognized tax benefits at beginning of year $ 4,169 $ 2,692 Additions based on prior year tax provisions — 118 Additions based on current year tax provisions 2,241 1,359 Unrecognized tax benefits at end of year $ 6,410 $ 4,169

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Summary of Future minimum lease payments under the leases for facilities	Future minimum lease payments under the leases for facilities as of December 31, 2019, are as follows (in thousands): Operating 2020 $ 6,247 2021 7,581 2022 6,794 2023 6,947 2024 and thereafter 45,410 Total future minimum lease commitments $ 72,979

Capital Stock and Stockholder_2

Capital Stock and Stockholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2019
Warrants and Rights Note Disclosure [Abstract]
Warrants to Purchase Common Stock	In connection with certain debt arrangements, the Company issued lenders the following warrants to purchase shares of Class A common stock which have an exercise term of 10 years: Issue Date Exercise Price Number April 2014 $ 0.21 43,750 September 2015 0.88 18,349 September 2016 1.07 79,000 February 2018 1.62 125,000

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement, Disclosure [Abstract]
Summary of the Company's stock option activity	A summary of the Company’s stock option activity under the Plans is as follows: Outstanding Weighted- Weighted- Aggregate Balance as of December 31, 2018 14,264,376 $ 1.91 8.2 $ 71,902,234 Granted 4,785,842 $ 19.05 Exercised (2,226,493 ) $ 1.69 Cancelled (905,482 ) $ 6.71 Balance as of December 31, 2019 15,918,243 $ 6.82 7.9 $ 1,105,222,370 Outstanding Weighted- Weighted- Aggregate Vested and exercisable as of December 31, 2019 7,362,304 $ 1.96 6.9 $ 546,973,399 Unvested and exercisable as of December 31, 2019 1,138,439 $ 5.90 8.3 $ 80,094,346
Summary of restricted shares issued under stock plan	A summary of these restricted shares issued under the 2012 Stock Plan is as follows: Number of Shares Weighted- Average Outstanding and unvested as of December 31, 2018 232,750 $ 2.80 Exercised 29,000 $ 11.48 Vested (123,500 ) $ 3.98 Outstanding and unvested as of December 31, 2019 138,250 $ 3.57
Stock Option Valuation Assumptions	The fair value of each employee option grant was estimated on the date of grant using the Black-Scholes option pricing model and the following assumptions for the periods indicated: Year Ended December 31, 2019 2018 2017 Expected volatility 40% – 53% 45% – 46% 45% – 48% Risk-free interest rate 1.5% – 2.5% 2.7% – 3.1% 1.9% – 2.3% Expected term 5.0 – 6.9 years 5.3 – 6.5 years 4.2 – 6.5 years Expected dividend — % — % — %
Schedule of Fair value of the Employee Stock Purchase Plan	For the year ended December 31, 2019, the fair value of the ESPP was estimated using the following assumptions. Year Ended December 31, 2019 Expected volatility 52% Risk-free interest rate 1.85% Expected term 0.7 years Expected dividend — %
Recorded stock-based compensation expense in the condensed consolidated statement of operations	The Company recorded stock-based compensation expense in the consolidated statement of operations for the periods presented as follows (in thousands): Year Ended December 31, 2019 2018 2017 Cost of revenue $ 325 $ 85 $ 44 Research and development 5,721 1,030 801 Selling, general and administrative 7,287 1,543 816 Total stock-based compensation expense $ 13,333 $ 2,658 $ 1,661

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Computation of basic and diluted net loss per share	The following table sets forth the computation of basic and diluted net loss per share for the periods indicated (in thousands, except share and per share data): Year Ended December 31, 2019 2018 2017 Net loss $ (31,251 ) $ (112,485 ) $ (18,762 ) Weighted average shares used in computing net loss per share, basic and diluted 39,091,366 13,392,273 11,587,751 Net loss per share, basic and diluted $ (0.80 ) $ (8.40 ) $ (1.62 )
Shares of common stock equivalents were excluded from the computation of diluted net loss per share	The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Year Ended December 31, 2019 2018 2017 Convertible preferred stock (on an if-converted — 67,704,278 59,730,213 Stock-options to purchase common stock 15,918,243 14,264,376 11,949,004 Shares subject to repurchase 138,250 232,750 301,372 Common stock warrants — 266,099 141,099 Shares committed under ESPP 56,159 — — Total 16,112,652 82,467,503 72,121,688

Selected Quarterly Information

Selected Quarterly Information (Tables)	12 Months Ended
	Dec. 31, 2019
Selected Quarterly Financial Information [Abstract]
Summary of quarterly information	The following tables present certain unaudited consolidated quarterly financial information for each of the eight quarters in the two-year Fiscal 2019 Quarter Ended (Unaudited) March 31 June 30 September 30 December 31 (in thousands, except per share data) Revenue $ 53,578 $ 55,819 $ 61,207 $ 75,289 Gross profit $ 39,613 $ 40,813 $ 45,727 $ 58,707 Net loss $ (3,636 ) $ (10,878 ) $ (9,603 ) $ (7,134 ) Net loss per share, basic and diluted $ (0.25 ) $ (0.70 ) $ (0.33 ) $ (0.07 ) Fiscal 2018 Quarter Ended (Unaudited) March 31 June 30 September 30 December 31 (in thousands, except per share data) Revenue $ 27,408 $ 31,744 $ 36,607 $ 50,554 Gross profit $ 23,438 $ 27,194 $ 31,366 $ 35,654 Net loss $ (15,693 ) $ (5,923 ) $ (15,345 ) $ (75,524 ) Net loss per share, basic and diluted $ (1.23 ) $ (0.45 ) $ (1.13 ) $ (5.40 )

Description of Business and B_2

Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Sep. 16, 2019	Sep. 15, 2019	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Entity incorporation, date of incorporation				Jul. 2, 2012
Common stock shares authorised				1,100,000,000	190,955,000
Preferred stock shares authorised				100,000,000	0
Common stock shares issued				96,241,596	14,549,801
Common stock shares outstanding				96,241,596	14,549,801
Common stock voting rights description				Each share of Class B common stock has the right to ten votes and each share of Class A common stock has the right to one vote per share.
Cash flow from operations				$ 34,627	$ (76,409)	$ (10,699)
Cash and cash equivalents				424,166	65,080	$ 47,857
Accumulated deficit				$ (262,367)	$ (231,116)
Common class A [Member]
Proceeds from Initial public offer	$ 410,800
Common stock shares converted		8,095,382	484,484
Common stock shares authorised				1,000,000,000
Common stock shares issued				20,972,166
Common stock shares outstanding				20,972,166	6,499,801
Common stock voting rights description				Each share of Class A common stock is entitled to one vote per share
Common stock conversion, description				convertible at any time into one share of Class A common stock
Common class B [Member]
Convertible preferred stock shares issued upon conversion		67,704,278
Common stock shares converted				8,050,000
Common stock shares authorised				100,000,000
Common stock shares issued				75,269,430
Common stock shares outstanding				75,269,430	8,050,000
Common stock voting rights description				Each share of Class B common stock is entitled to ten votes per share
IPO [Member] | Common class A [Member]
Common stock new issue shares	11,500,000
IPO offer price per share	$ 39
Offering costs, underwriting commissions and discounts	$ 37,700
IPO [Member] | Common class A [Member] | Underwriter offer [Member]
Common stock new issue shares	1,500,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2019USD ($)Segment	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Number of operating segment | Segment	1
Unrealised gains losses on money market instruments	$ 0	$ 0
Allowance For doubtful debts	0	300,000
Impairment of long lived assets	$ 0	0
Product warranty	The Company generally provides a one-year warranty on its instruments.
Foreign currency transaction losses	$ 100,000	(300,000)	$ 100,000
Advertising Costs	1,500,000	$ 700,000	$ 200,000
Restricted Cash For Letter Of Credit [Member]
Restricted cash and cash equivalents	5,000,000
Restricted Cash For Bonds [Member]
Restricted cash and cash equivalents	45,200,000
Restricted Cash For Esxrow [Member]
Restricted cash and cash equivalents	$ 2,100,000
Maximum [Member]
Percentage of tax benefit recognised	50.00%
Recognition of right to use assets	$ 43,000,000
Lease Liabilities	59,000,000
Minimum [Member]
Recognition of right to use assets	33,000,000
Lease Liabilities	$ 49,000,000
Revenue [Member]
Concentration risk percentage	10.00%	10.00%	10.00%
Accounts receivable [Member]
Concentration risk percentage	10.00%	10.00%
Fair value, inputs, level 1 [Member] | Money market funds [Member]
Fair value of money market instruments	$ 398,500,000	$ 44,500,000
Unrealised gains losses on money market instruments	$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Cash Equivalents and Restricted Cash (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	$ 424,166	$ 65,080	$ 47,857
Restricted cash	52,327	5,008
Total cash, cash equivalents and restricted cash	$ 476,493	$ 70,088	$ 47,857	$ 41,743

Asset Acquisition - Additional

Asset Acquisition - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended			10 Months Ended	11 Months Ended	12 Months Ended
	Oct. 31, 2019	Nov. 30, 2018	Mar. 31, 2018	Oct. 31, 2019	Nov. 30, 2018	Dec. 31, 2019	Dec. 31, 2018
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
In-process research and development							$ 62,363
Intangible assets [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
Intangible assets						$ 425
Epinomics Inc [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
Business acquisition, Consideration net						22,200
Business acquisition costs						300
In-process research and development							$ 22,200
Epinomics Inc [Member] | Due upon closing of acquisition [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
Business acquisition, Consideration net			$ 6,200
Epinomics Inc [Member] | Due upon amendment and assignment of license agreement [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
Business acquisition, Consideration net						$ 16,000
BD Entities [Member] | Intellectual Property [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
Purchase price of asset acquired	$ 25,000
Asset Acquisition, Annual Payments	$ 6,250			$ 6,250
Asset Acquisition, Consideration Payment Terms	To be paid in annual amounts of $6.25 million over four years beginning in January 2020
Spatial Transcriptomics [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
Business acquisition, Consideration net					$ 38,600
Business acquisition costs		$ 500			500
In-process research and development					$ 36,900
Spatial Transcriptomics [Member] | Patents [Member]
Research and Development Assets Acquired Other than Through Business Combination [Line Items]
Purchase price of asset acquired		$ 36,900

Asset Acquisitions - Summary of

Asset Acquisitions - Summary of Assets Acquired and Liabilities Assumed (Detail) $ in Thousands	Dec. 31, 2019USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Other assets and liabilities	$ 1,237
Total net assets acquired	38,561
In-process research and development [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets	36,899
Intangible assets [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Intangible assets	$ 425

Other Financial Statement Inf_3

Other Financial Statement Information - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended								10 Months Ended	12 Months Ended
	Oct. 31, 2019	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Oct. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Transaction price allocated to remaining performance obligations		$ 4,100									$ 4,100
Remaining performance obligations percentage		80.00%									80.00%
Contract liability		$ 4,131				$ 3,497					$ 4,131	$ 3,497
Contract Liability, short-term portion		3,297				2,395					3,297	2,395
Revenues		$ 75,289	$ 61,207	$ 55,819	$ 53,578	$ 50,554	$ 36,607	$ 31,744	$ 27,408		245,893	146,313	$ 71,085
Depreciation of Property Plant and Equipment											$ 6,700	$ 3,800	$ 4,300
Finite-lived Intangible Assets, Fair Value Disclosure	$ 22,100									$ 22,100
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction: 2020-09-30
Expected period of revenue recognition		12 months									12 months
BD Entities [Member] | Intellectual Property [Member]
Asset Acquisition, Annual Payments	6,250									6,250
Purchase price of asset acquired	25,000
Accrued Expenses And Other Current Liabilities [Member]
Present value of annual payments of intangible assets	$ 21,100									$ 21,100
Revenue [Member]
Revenues											$ 2,300
Percentage Of Revenue											10.00%	10.00%	10.00%
US (included in North America) | Geographic Concentration Risk [Member] | Revenue [Member]
Percentage Of Revenue											54.00%	55.00%

Other Financial Statement Inf_4

Other Financial Statement Information - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Purchased materials	$ 6,436	$ 3,052
Work in progress	3,996	2,553
Finished goods	4,838	2,965
Inventory	$ 15,270	$ 8,570

Other Financial Statement Inf_5

Other Financial Statement Information - Schedule Of Property Plant And Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property and equipment, gross	$ 67,876	$ 25,210
Accumulated depreciation and amortization	(19,055)	(14,083)
Property and equipment, net	48,821	11,127
Laboratory equipment and machinery
Property and equipment, gross	22,400	14,616
Computer equipment
Property and equipment, gross	4,991	3,303
Furniture and fixtures
Property and equipment, gross	4,143	1,002
Leasehold improvements
Property and equipment, gross	33,936	3,342
Construction in progress
Property and equipment, gross	$ 2,406	$ 2,947

Other Financial Statement Inf_6

Other Financial Statement Information - Intangible Assets, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 22,912	$ 787
Accumulated Amortization	(546)	(145)
Intangibles, Net	22,366	642
Technology Licenses [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	22,504	379
Accumulated Amortization	(440)	(136)
Intangibles, Net	22,064	243
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	204	204
Accumulated Amortization	(32)	(3)
Intangibles, Net	172	201
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	204	204
Accumulated Amortization	(74)	(6)
Intangibles, Net	$ 130	$ 198

Other Financial Statement Inf_7

Other Financial Statement Information - Annual Amortization Of Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Finite Lived Intangible Assets Amortization [Abstract]
2020	$ 1,630
2021	1,625
2022	1,563
2023	1,532
2024	1,503
2025	1,500
Thereafter	13,013
Total	$ 22,366	$ 642

Other Financial Statement Inf_8

Other Financial Statement Information - Schedule of Accrued Compensation and Related Benefits (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accrued bonus	$ 6,154	$ 3,545
Accrued commissions	2,473	2,299
Other	3,767	1,203
Accrued compensation and related benefits	$ 12,394	$ 7,047

Other Financial Statement Inf_9

Other Financial Statement Information - Schedule of Accrued Expense And Other Current Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accrued legal expenses	$ 4,375	$ 1,769
Accrued license fees	6,183
Accrued royalties for licensed technologies	2,025	1,571
Accrued property and equipment	3,885	990
Accrued consulting	1,173	741
Product warranties	467	804
Customer deposits	1,304	381
Taxes payable	1,087	738
Other	3,949	2,947
Accrued expenses and other current liabilities	$ 24,448	$ 9,941

Other Financial Statement In_10

Other Financial Statement Information - Schedule of Changes in the Reserve for Product Warranties (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Beginning of period	$ 804	$ 174
Additions charged to cost of revenue	741	1,685
Repairs and replacements	(1,078)	(1,055)
End of period	$ 467	$ 804

Other Financial Statement In_11

Other Financial Statement Information - Summary Of The Change In Contract Liabilities (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Change in Contract with Customer, Liability [Abstract]
Balance as of January 1	$ 3,497
Revenue recognized that was included in the contract liability at the beginning of the year	2,250
Revenue deferred excluding amounts recognized as revenue during the period	2,884
Balance as of December 31	$ 4,131

Other Financial Statement In_12

Other Financial Statement Information - Schedule of Revenue by Source (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenues	$ 75,289	$ 61,207	$ 55,819	$ 53,578	$ 50,554	$ 36,607	$ 31,744	$ 27,408	$ 245,893	$ 146,313	$ 71,085
Instuments [Member]
Revenues									34,945	36,540	24,467
Consumables [Member]
Revenues									206,878	107,616	46,192
Service [Member]
Revenues									$ 4,070	$ 2,157	$ 426

Other Financial Statement In_13

Other Financial Statement Information - Schedule of Revenue by geography (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenues	$ 75,289	$ 61,207	$ 55,819	$ 53,578	$ 50,554	$ 36,607	$ 31,744	$ 27,408	$ 245,893	$ 146,313	$ 71,085
North America [Member]
Revenues									139,758	85,132	43,622
Europe, Middle East and Africa [Member]
Revenues									58,004	35,812	18,602
China [Member]
Revenues									29,920	15,075	3,171
Asia Pacific [Member]
Revenues									$ 18,211	$ 10,294	$ 5,690

Debt - Additional information (

Debt - Additional information (Detail) - USD ($)	Feb. 28, 2018	Sep. 30, 2016	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2019	Jan. 31, 2018
Debt Instrument [Line Items]
Term loan borrowed				$ 19,512,000
Term loan outstanding			$ 29,719,000
Revolving line of credit borrowed			$ 11,000,000
Estimated fair value of the warrants	$ 150,000
Common stock warrants issued					141,099
Penal interest rate spread			5.00%
Debt Instrument, Debt Default, Description of Violation or Event of Default			Immediately upon the occurrence and during the continuance of an event of default, including the noncompliance with the above covenants, the lender may increase the interest rate per annum by 5.0% above the rate that would be otherwise applicable; stop future loan advances; require the Company to deposit 105% of any undrawn letters of credit, or 110% if the letter of credit was denominated in a foreign currency; and take control over all assets collateralizing the loan and take necessary means to protect the collateral.
Common class A [Member] | Warrant [Member]
Debt Instrument [Line Items]
Number Of Securities Called By Warrants			266,099
Foreign Line of Credit [Member]
Debt Instrument [Line Items]
Deposit percentage			110.00%
Revolving Credit Facility
Debt Instrument [Line Items]
Debt Instrument, maximum borrowing capacity			$ 25,000,000			$ 25,000,000
Debt Instrument, Expiration Date			Dec. 30, 2022
Line of credit facility available as a percentage of receivables			80.00%
Line of credit facility interest rate description			Principal amounts outstanding under the revolving line of credit accrue interest at the greater of a floating per annum rate equal to the greater of The Wall Street Journal prime rate plus 0.25% or 4.5% and are repayable monthly
Non refundable annual commitment fee			$ 62,500
Revolving line of credit borrowed			11,000,000
Line of credit facility, termination fee			250,000
Line of credit, outstanding			$ 0
Revolving Credit Facility | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument spread on variable rate			0.25%
Revolving Credit Facility | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument spread on variable rate			4.50%
Line of Credit [Member]
Debt Instrument [Line Items]
Debt Instrument, maximum borrowing capacity							$ 5,000,000
Deposit percentage			105.00%
Tranche A | Term Loan [Member]
Debt Instrument [Line Items]
Term loan borrowed		$ 10,600,000
Amended Tranche A | Warrant [Member]
Debt Instrument [Line Items]
Exercise price per share	$ 1.62
Amended Tranche A | Term Loan [Member]
Debt Instrument [Line Items]
Term loan outstanding	$ 10,500,000
Number Of Securities Called By Warrants	125,000
Long-Term Debt | Term Loan [Member]
Debt Instrument [Line Items]
Term loan frequency of payment terms			Monthly payments of interest were due under the Amended Tranche A term loan through June 30, 2019, with monthly installments of principal and interest due for 42 months thereafter. If the Amended Tranche B was borrowed, monthly installments of principal and interest were to be reduced to 36 months. In June 2019, the Company's loan and security agreement was amended to extend the Company's option to borrow the Amended Tranche B through December 31, 2019.
Term loan description of variable interest rate			The term loan accrues interest at the greater of the floating per annum rate equal to the greater of The Wall Street Journal prime rate plus 2.0% or 6.25%
Interest expense due			$ 1,800,000
One time fees paid			$ 50,000
Long-Term Debt | Term Loan [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument spread on variable rate			2.00%
Long-Term Debt | Term Loan [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument spread on variable rate			6.25%
Long-Term Debt | Term Loan [Member] | Before the first anniversary of loan closing
Debt Instrument [Line Items]
Prepayment fees percentage			3.00%
Long-Term Debt | Term Loan [Member] | After the first anniversary of loan closing to before the second anniversary of loan closing
Debt Instrument [Line Items]
Prepayment fees percentage			2.00%
Long-Term Debt | Term Loan [Member] | After the second anniversary of loan closing to before maturity date
Debt Instrument [Line Items]
Prepayment fees percentage			1.00%
Long-Term Debt | Amended Tranche A | Term Loan [Member]
Debt Instrument [Line Items]
Term loan borrowed	$ 19,500,000		$ 30,000,000
Long-Term Debt | Amended Tranche B | Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument, additional borrowing capacity			$ 20,000,000

Debt - Summary of Aggregate Ann

Debt - Summary of Aggregate Annual Payments due on the term loan - (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
2020	$ 11,744
2021	11,055
2022	12,170
Total payments	34,969
Less: amount representing interest	(4,969)
Total term loan	30,000
Less: unamortized debt discount	(281)
Total term loan, net of debt discount	29,719
Less: current portion	(9,882)	$ (4,187)
Non-current portion	$ 19,837	$ 25,489

Income Tax - Summary Of Loss Be

Income Tax - Summary Of Loss Before Provision For Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Contingency [Line Items]
Loss Before Provision For Income Taxes	$ (31,033)	$ (112,398)	$ (18,741)
United States [Member]
Income Tax Contingency [Line Items]
Loss Before Provision For Income Taxes	(35,675)	(77,517)
International [Member]
Income Tax Contingency [Line Items]
Loss Before Provision For Income Taxes	$ 4,642	$ (34,881)

Income Tax - Summary Of Reconci

Income Tax - Summary Of Reconciliation Of The Federal Statutory Income Tax Provision (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Schedule Of Reconciliation Of The Federal Statutory Income Tax Provision To The Effective Income Tax [Abstract]
Income tax provision at statutory rate	$ (6,517)	$ (23,604)
State taxes, net	(2,958)	(4,479)
Tax credits	(2,684)	(1,631)
Foreign taxes	101	41
Stock-based compensation	1,032	421
Change in valuation allowance	10,783	19,133
Acquisition related expenses	116	10,143
Other	345	63
Total provision for income taxes	$ 218	$ 87	$ 21

Income Tax - Summary Of Major C

Income Tax - Summary Of Major Components Of Deferred Tax Assets And Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets
Net operating loss carryforwards	$ 28,878	$ 31,031
Research and development tax credits	15,961	10,874
Accruals and reserves	23,804	12,612
Other	2,766	1,616
Total deferred tax assets	71,409	56,133
Valuation allowance	(66,456)	(55,673)
Net deferred tax assets	4,953	460
Deferred tax liabilities
Fixed assets	(4,946)	$ (460)
Net deferred taxes	$ 7

Income Tax - Summary Of Unrecog

Income Tax - Summary Of Unrecognized Gross Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Unrecognized tax benefits at beginning of year	$ 4,169	$ 2,692
Additions based on prior year tax provisions		118
Additions based on current year tax provisions	2,241	1,359
Unrecognized tax benefits at end of year	$ 6,410	$ 4,169

Income Tax - Additional Informa

Income Tax - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Nov. 01, 2013
Operating Loss Carryforwards [Line Items]
Provision for income taxes	$ 218	$ 87	$ 21
Change in valuation allowance	$ 10,800	19,300
Operating Loss Carryforwards, Limitation Amount				$ 4,800
Tax credit carryforward, Percentage	50 percentage
Operating Loss Carryforwards expiration year	2032
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 87,000
Tax Credit Carryforward, Amount	11,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	110,700	$ 6,500
Tax Credit Carryforward, Amount	$ 12,300

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Thousands

1 Months Ended

3 Months Ended

10 Months Ended

12 Months Ended

Oct. 31, 2019USD ($)

Aug. 31, 2019USD ($)

Nov. 30, 2018USD ($)

Jun. 30, 2018USD ($)

Dec. 31, 2018USD ($)

Oct. 31, 2019USD ($)

Dec. 31, 2019USD ($)

Dec. 31, 2019EUR (€)

Dec. 31, 2018USD ($)

Dec. 31, 2017USD ($)

Mar. 31, 2020USD ($)

Sep. 13, 2019USD ($)

Accrual provision

$ 1,502

$ 30,580

Minimum purchase commitment

6,400

Contractual obligation

4,200

Operating leases rent expense

6,800

3,500

$ 1,000

Milestone Payment [Member] | Subsequent Event [Member]

Other Commitment

$ 5,000

Bio Rad [Member]

Company bear the legal cost of court | €

€ 61,000

Letter of Credit [Member]

Letter of credit maximum borrowing capacity

5,000

Intellectual Property [Member]

Minimum purchase commitment

4,900

BD Entities [Member]

Weighted average amortization period of intangible asset

15 years

BD Entities [Member] | Intellectual Property [Member]

Purchase price of asset acquired

$ 25,000

Fair value of asset acquired

22,100

$ 22,100

Asset Acquisition, Annual Payments

$ 6,250

$ 6,250

Prognosys [Member] | Intellectual Property [Member]

Purchase price of asset acquired

$ 3,300

Bio RadLaboratories Inc [Member]

Damages awarded

$ 35,000

$ 24,000

Royalty percentage on sales

15.00%

Royalty expense

$ 7,400

Loss contingency

$ 38,000

68,700

38,000

Bond amount

52,000

$ 52,000

Potential Decrease in Pre Security Bond Amount

$ 35,000

Potential Increased Pre Security Bond Amount

$ 61,000

Bio RadLaboratories Inc [Member] | Assets Held In Trust [Member]

Cash collateral

$ 45,000

Bio RadLaboratories Inc [Member] | Operating Expense [Member]

Accrual provision

30,600

Pre and post judgment interest

1,500

30,600

Bio RadLaboratories Inc [Member] | Cost of Sales [Member]

Royalty expense

$ 29,200

$ 7,400

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Future minimum lease payments under the leases for facilities (Details) $ in Thousands	Dec. 31, 2019USD ($)
Leases [Abstract]
2020	$ 6,247
2021	7,581
2022	6,794
2023	6,947
2024 and thereafter	45,410
Total future minimum lease commitments	$ 72,979

Capital Stock and Stockholder_3

Capital Stock and Stockholders' Deficit - Summary Of Warrants to Purchase Common Stock (Detail)	Dec. 31, 2019$ / sharesshares
April 2014 [Member]
Class of Warrant or Right [Line Items]
Exercise price per share | $ / shares	$ 0.21
Number of Shares | shares	43,750
September 2015 [Member]
Class of Warrant or Right [Line Items]
Exercise price per share | $ / shares	$ 0.88
Number of Shares | shares	18,349
September 2016 [Member]
Class of Warrant or Right [Line Items]
Exercise price per share | $ / shares	$ 1.07
Number of Shares | shares	79,000
February 2018 [Member]
Class of Warrant or Right [Line Items]
Exercise price per share | $ / shares	$ 1.62
Number of Shares | shares	125,000

Capital Stock and Stockholder_4

Capital Stock and Stockholders' Deficit - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Common stock authorized		1,100,000,000	190,955,000
Shares Of Capital Stock Authorized		1,200,000,000
Common stock issued		96,241,596	14,549,801
Common Stock Outstanding		96,241,596	14,549,801
Common Stock, Par Value		$ 0.00001	$ 0.00001
Common stock voting rights		Each share of Class B common stock has the right to ten votes and each share of Class A common stock has the right to one vote per share.
Preferred stock shares authorised		100,000,000	0
Common Class A Warrant [Member]
Fair value of shares of Class A common stock		$ 1.62
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		125,000
Fair Value of Warrants		$ 150,000
Risk-free interest rate		1.54%
Contractual Term		10 years
Estimated volatility		68.00%
Common class A [Member]
Common stock authorized		1,000,000,000
Common stock issued		20,972,166
Common Stock Outstanding		20,972,166	6,499,801
Common Stock, Par Value		$ 0.00001
Common stock voting rights		Each share of Class A common stock is entitled to one vote per share
Common class A [Member] | Warrant [Member]
Cashless exercise of Class A common stock warrants, shares	261,024
Common class B [Member]
Common stock authorized		100,000,000
Common stock issued		75,269,430
Common Stock Outstanding		75,269,430	8,050,000
Common Stock, Par Value		$ 0.00001
Common stock voting rights		Each share of Class B common stock is entitled to ten votes per share
Convertible preferred stock [Member]
Preferred stock shares authorised		100,000,000

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Total repurchase liability related to the unvested early exercised options	$ 494,000
Total repurchase liability related to the unvested early exercised options		$ 652,000
2019 Omnibus Incentive Plan [Member]
contractual term	10 years
Percentage increase in shares on stock outstanding	5.00%
Weighted-average grant date fair value of options	$ 13.20	$ 2.04	$ 0.66
Stock options grant date fair value	$ 13.20	$ 2.04	$ 0.66
Unrecognized stock-based compensation	$ 57,800,000
Weighted-average period of recognition for stock options	3 years 2 months 12 days
Intrinsic value of stock options exercised	$ 30,500,000	$ 3,300,000	$ 800,000
2019 Omnibus Incentive Plan [Member] | Minimum [Member]
Exercise price percentage on fair market value	100.00%
2019 Employee Stock Purchase Plan [Member]
Offering period	6 months
Common stock purchased under plan	0
Percentage increase in shares on stock outstanding	1.00%
Employee contribution percentage	15.00%
Weighted-average grant date fair value of options	$ 12.60
Stock options grant date fair value	$ 12.60
Unrecognized stock-based compensation	$ 1,000,000
Weighted-average period of recognition for stock options	4 months 24 days
Common Class A [Member] | 10x Genomics, Inc. 2012 Stock Plan [Member]
Common stock issuable upon the exercise of stock options	15,225,893	24,782,088
Common Class A [Member] | 2019 Omnibus Incentive Plan [Member]
Common stock issuable upon the exercise of stock options	11,000,000
Common stock available for sale	11,000,000
Common Class A [Member] | 2019 Employee Stock Purchase Plan [Member]
Common stock reserved for issuance	2,000,000

Equity Incentive Plans - Summar

Equity Incentive Plans - Summary Of Company's Stock Option Activity (Detail) - 2019 Omnibus Incentive Plan [Member] - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance	14,264,376
Outstanding Options - Granted	4,785,842
Exercised	(2,226,493)
Outstanding Options - Cancelled	(905,482)
Ending balance	15,918,243	14,264,376
Weighted-Average exercise price - Beginning balance	$ 1.91
Weighted-Average exercise price - Granted	19.05
Weighted-Average exercise price - Exercised	1.69
Weighted-Average exercise price - Cancelled	6.71
Weighted-Average exercise price - Ending balance	$ 6.82	$ 1.91
Weighted- Average Remaining Terms (Years)	7 years 10 months 24 days	8 years 2 months 12 days
Aggregate intrinsic value	$ 1,105,222,370	$ 71,902,234
Outstanding option - Vested and exercisable	7,362,304
Weighted Average Exercise Price - Vested exercisable	$ 1.96
Weighted- Average Remaining Terms (Years) - Vested and exercisable	6 years 10 months 24 days
Aggregate intrinsic value - Vested and exercisable	$ 546,973,399
Outstanding option - Unvested and exercisable	1,138,439
Weighted Average Exercise Price - Unvested exercisable	$ 5.90
Weighted- Average Remaining Terms (Years) - Vested and exercisable	8 years 3 months 18 days
Aggregate intrinsic value - Unvested and exercisable	$ 80,094,346

Equity Incentive Plans - Summ_2

Equity Incentive Plans - Summary Of Early Exercise of Options (Detail) - Two Thousand Twelve Stock Plan Plan [Member]	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Vested | shares	(123,500)
Weighted-Average exercise price - Exercised | $ / shares	$ 11.48
Weighted-Average exercise price - Vested | $ / shares	$ 3.98
Unvested [Member]
Beginning balance | shares	232,750
Exercised | shares	29,000
Ending balance | shares	138,250
Weighted-Average exercise price - Beginning balance | $ / shares	$ 2.80
Weighted-Average exercise price - Ending balance | $ / shares	$ 3.57

Equity Incentive Plans - Summ_3

Equity Incentive Plans - Summary Of Stock Option Valuation Assumptions (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	40.00%	45.00%	45.00%
Risk-free interest rate	1.50%	2.70%	1.90%
Expected term	5 years	5 years 3 months 18 days	4 years 2 months 12 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	53.00%	46.00%	48.00%
Risk-free interest rate	2.50%	3.10%	2.30%
Expected term	6 years 10 months 24 days	6 years 6 months	6 years 6 months

Equity Incentive Plans - Summ_4

Equity Incentive Plans - Summary Of Fair Value Of The ESPP (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend
2019 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	52.00%
Risk-free interest rate	1.85%
Expected term	8 months 12 days

Equity Incentive Plans - Record

Equity Incentive Plans - Recorded Stock-Based Compensation Expense in the Condensed Consolidated Statement of Operations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	$ 13,333	$ 2,658	$ 1,661
Cost of revenue [Member]
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	325	85	44
Research and development [Member]
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	5,721	1,030	801
Selling, general and administrative [Member]
Share-based Payment Arrangement, Expensed [Line Items]
Stock-based compensation expense	$ 7,287	$ 1,543	$ 816

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
Net loss	$ (7,134)	$ (9,603)	$ (10,878)	$ (3,636)	$ (75,524)	$ (15,345)	$ (5,923)	$ (15,693)	$ (31,251)	$ (112,485)	$ (18,762)
Weighted average shares used in computing net loss per share, basic and diluted									39,091,366	13,392,273	11,587,751
Net loss per share, basic and diluted	$ (0.07)	$ (0.33)	$ (0.70)	$ (0.25)	$ (5.40)	$ (1.13)	$ (0.45)	$ (1.23)	$ (0.80)	$ (8.40)	$ (1.62)

Net Loss Per Share - Shares of

Net Loss Per Share - Shares of Common Stock Equivalents Were Excluded From The Computation of Diluted Net Loss Per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	16,112,652	82,467,503	72,121,688
Convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		67,704,278	59,730,213
Stock-options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	15,918,243	14,264,376	11,949,004
Shares subject to repurchase [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	138,250	232,750	301,372
Common stock warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		266,099	141,099
Shares committed under ESPP [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	56,159

Selected Quarterly Informatio_2

Selected Quarterly Information - Summary Of Quarterly Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Selected Quarterly Financial Information [Abstract]
Revenue	$ 75,289	$ 61,207	$ 55,819	$ 53,578	$ 50,554	$ 36,607	$ 31,744	$ 27,408	$ 245,893	$ 146,313	$ 71,085
Gross profit	58,707	45,727	40,813	39,613	35,654	31,366	27,194	23,438	184,860	117,652	60,525
Net loss	$ (7,134)	$ (9,603)	$ (10,878)	$ (3,636)	$ (75,524)	$ (15,345)	$ (5,923)	$ (15,693)	$ (31,251)	$ (112,485)	$ (18,762)
Net loss per share, basic and diluted	$ (0.07)	$ (0.33)	$ (0.70)	$ (0.25)	$ (5.40)	$ (1.13)	$ (0.45)	$ (1.23)	$ (0.80)	$ (8.40)	$ (1.62)